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Guarda lontano,  
e quando pensi di aver guardato lontano, 
guarda ancora più lontano. 
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SUMMARY	
Vaccines are complex multi-component products, in which an interdependent 
relationship among constituents exists: the concomitant inclusion of antigens, 
adjuvants, and excipients is essential to guarantee the efficacy of the final product. 
To stimulate the immune system and raise immunogenicity against highly purified 
vaccine components most likely adjuvants are required, thus becoming more and 
more crucial elements of modern vaccine formulations. Physico-chemical and 
functional attributes of all components and of the whole vaccine formulation have 
to be controlled before injection. However, often characterization challenges are 
experienced with the currently available analytical techniques, also because of 
interferences with adjuvants.  
In this thesis adjuvants were evaluated with the aim to improve quality and 
immunogenicity of combination vaccines, in which the inclusion of multiple 
antigenic components contributes to enhanced complexity of the final product.  
In detail, three virulence factors of the Gram negative bacterium Bordetella 
pertussis (pertussis toxin PT, filamentous heamagglutinin FHA, and pertactin 69K) 
were chosen as model antigens. Currently licensed acellular pertussis (aP) vaccines 
are combined with diphtheria and tetanus toxoids in the DTaP/TdaP vaccine, which 
is considered a cornerstone of combination vaccines. This vaccine is typically 
adjuvanted with aluminum salts, known to induce mainly a humoral immune 
response which has been associated with recent pertussis outbreaks reported in 
many countries. This suggests that existing vaccines may not be ideal to provide 
protection against the disease. Thus, a pharmaceutical sciences approach focusing 
on adjuvants was applied to investigate the potential improvement of acellular 
pertussis vaccines through promotion of the analytical characterization and rational 
polarization of the quality of immune responses. 
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Improved in vitro characterization assays for combination vaccines adjuvanted 
with aluminum hydroxide 
Vaccines in vitro characterization is required to identify optimal formulation 
conditions to ensure physical, chemical, and biological integrity of antigens and 
adjuvants. Analytical methods currently in use are mostly suitable for the 
characterization of unformulated antigens – requiring the complete desorption from 
aluminum-based adjuvants - and are not always able to reveal individual antigens in 
vaccine combinations. Here, the Luminex technology is proposed as proof of 
concept for the development of an improved analytical method for vaccine 
characterization, based on the use of specific antibodies bound to magnetic 
microspheres presenting unique digital signatures for simultaneous recognition of 
respective antigens in the entire formulation. TdaP combination vaccines were 
chosen as a model to develop an assay able to quantify acellular pertussis antigens 
and their levels of adsorption to adjuvant at the same time. This assay was directly 
applicable on the commercial vaccine product, avoiding any laborious procedures 
for separation of the antigens from the adjuvant. Accurate and reproducible 
quantification of aP antigens in TdaP vaccine has been achieved in a range between 
0.78 and 50 ng/mL, providing information on antigen identity, quantity, and degree 
of adsorption to aluminum hydroxide. Importantly, the Luminex characterization 
method has the potential to be further evaluated as correlate of in vitro potency 
assays - ideally allowing reducing in vivo animal studies. 
In vivo evaluation of novel adjuvants for improved aP-containing combination 
vaccines 
The successful approach of combining diphtheria, tetanus and pertussis antigens 
into a single vaccine has become the cornerstone of pediatric and adults 
immunization programs. Yet, even if vaccination coverage is high, a resurgence of 
pertussis has been recently reported in many countries suggesting that current 
vaccines may not provide adequate long-lasting protection. 
In order to develop pertussis-containing vaccines able to induce a more durable and 
better tailored immune response different approaches have been proposed, 
including the use of novel adjuvants. Currently licensed pertussis vaccines contain 
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aluminum salts, which are the most common adjuvants for human use. By inducing 
mainly humoral immune responses aluminum salts might not be ideal for providing 
protection against pathogens which require a more cellular immune response, such 
as Bordetella pertussis.  
Therefore, alternative adjuvants that induce more balanced T-helper profiles or even 
Th1-prone responses might be more adequate. In this project, we tested three 
different adjuvants: MF59 emulsion adjuvant – that induces a mixed Th1/2 response 
- as well as the combination of a Toll-Like Receptor 4 agonist (TLR4a) or a Toll-
Like Receptor 7 agonist (TLR7a) with aluminum hydroxide to induce even further 
Th1 polarization. The adjuvants were evaluated for their ability to improve immune 
responses against a TdaP vaccine containing three B. pertussis antigens: genetically 
detoxified pertussis toxin (PT-9K/129G), filamentous hemagglutinin (FHA) and 
pertactin (69K).  
The quicker onset of serum antibody titers and the changed quality of the antibody 
responses induced by the adjuvants evaluated here fully support the potential 
replacement of aluminum salts with alternative adjuvants to enhance pertussis 
immunogenicity in aP-containing combination vaccines. 
Conclusions 
Overall, the collected results suggested the possibility to modulate quality and 
efficacy of a complex vaccine product by carefully working on the adjuvant 
component. Improving the analytical characterization of vaccines while addressing 
a rational polarization of immune responses are proposed as effective strategies to 
be pursued for the development of next generation combination vaccines. 
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R IASSUNTO	
I vaccini sono prodotti complessi costituiti da diversi elementi tra i quali esiste un 
rapporto d’interdipendenza: la presenza concomitante di antigeni, adiuvanti, ed 
eccipienti è essenziale per garantire l'efficacia del prodotto finale. Gli adiuvanti 
sono spesso necessari per stimolare il sistema immunitario e aumentare 
l'immunogenicità di un vaccino composto di antigeni molto purificati: diventano 
perciò sempre più importanti nelle moderne formulazioni di vaccini. Le proprietà 
fisico-chimiche di tutti gli elementi e dell'intera formulazione e devono essere 
controllate prima dell'iniezione. Tuttavia, le tecniche analitiche ora disponibili 
spesso interferiscono con gli adiuvanti, e problemi di caratterizzazione sono 
incontrati. 
In questa tesi gli adiuvanti sono stati sfruttati con l'obiettivo di indagare la 
possibilità di migliorare la qualità e l'immunogenicità dei vaccini combinati, nei 
quali l'inclusione di più elementi antigenici contribuisce alla maggiore complessità 
del prodotto finale. 
In particolare, tre fattori di virulenza del batterio Gram negativo Bordetella 
pertussis (tossina della pertosse PT, emoagglutinina filamentosa FHA, e pertactina 
69K) sono stati scelti come antigeni modello. I vaccini acellulari di pertosse (aP) 
attualmente autorizzati sono combinati con le tossine inattivate di difterite e tetano 
nel vaccino DTaP/TdaP, che è considerato la pietra miliare dei vaccini combinati. 
Questo vaccino è tipicamente adiuvato con sali di alluminio, noti per indurre 
prevalentemente una risposta immunitaria umorale che è stata associata con le 
recenti epidemie di pertosse segnalate in molti paesi. Ciò suggerisce che il vaccino 
esistente non sia ideale per fornire una protezione contro la malattia. Pertanto, un 
approccio basato sulle scienze farmaceutiche e focalizzato sugli adiuvanti è stato 
applicato per studiare il potenziale miglioramento dei vaccini acellulari di pertosse, 
attraverso lo sviluppo della caratterizzazione analitica e la razionale polarizzazione 
della qualità della risposta immunitaria. 
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Sviluppo di saggi di caratterizzazione in vitro per vaccini combinati 
adiuvantati con idrossido di alluminio 
La caratterizzazione analitica in vitro è necessaria per individuare le condizioni di 
formulazione ottimali che garantiscano l'integrità fisica, chimica e biologica di 
antigeni e adiuvanti. I metodi analitici ora in uso sono soprattutto adatti per la 
caratterizzazione di antigeni non formulati - richiedendo quindi il desorbimento 
completo dalla superfice degli adiuvanti a base di alluminio - e non sempre sono in 
grado di distinguere tra i singoli antigeni contenuti nei vaccini combinati. In questa 
tesi la tecnologia Luminex è proposta come proof of concept per lo sviluppo di un 
miglior metodo analitico per la caratterizzazione di vaccini. Questo metodo è basato 
sull'utilizzo di anticorpi specifici legati a microsfere magnetiche che sono 
univocamente riconoscibili tramite una firma digitale permettendo quindi 
l’identificazione simultanea dei rispettivi antigeni formulati nel vaccino.  
I vaccini combinati TdaP sono stati scelti come modello per sviluppare un saggio in 
grado di quantificare simultaneamente gli antigeni acellulari della pertosse (aP) e il 
loro grado di adsorbimento all’adiuvante. Questo saggio è direttamente applicabile 
al vaccino commerciale, evitando qualsiasi procedura laboriosa per la separazione 
degli antigeni dall’adiuvante. Una quantificazione accurata e riproducibile degli 
antigeni aP nel vaccino TdaP è stata ottenuta in un intervallo di concentrazioni 
compreso tra 0,78 e 50 ng/mL, fornendo informazioni sull'identità degli antigeni, la 
loro quantità e il grado di assorbimento alla superficie dell’idrossido di alluminio. Il 
metodo di caratterizzazione sviluppato sulla tecnologia Luminex ha la potenzialità 
di essere valutato come test di in vitro potency - permettendo idealmente la 
riduzione degli studi effettuati sugli animali. 
Valutazione in vivo di nuovi adiuvanti per migliorare i vaccini combinati 
contenenti aP 
L'approccio di combinare gli antigeni di difterite, tetano e pertosse in un unico 
vaccino è diventato il fondamento dei programmi d’immunizzazione pediatrici e per 
adulti. Nonostante l’elevata copertura vaccinale, una riacutizzazione dei casi di 
pertosse è stata recentemente registrata in molti paesi, suggerendo che i vaccini 
attuali non possono fornire un’adeguata protezione di lunga durata. 
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Diversi approcci sono stati proposti al fine di sviluppare vaccini in grado di indurre 
una risposta immunitaria più durevole e più adeguata contro la pertosse, tra cui l'uso 
di nuovi adiuvanti. I vaccini contro la pertosse ora autorizzati contengono sali di 
alluminio, che sono gli adiuvanti più comuni per uso umano. Inducendo 
principalmente risposte immunitarie umorali, i sali di alluminio non sono ideali per 
fornire protezione contro gli agenti patogeni che richiedono una risposta 
immunitaria cellulare, come ad esempio Bordetella pertussis. 
Pertanto, altri adiuvanti che stimolino l’induzione di cellule Th1 potrebbero essere 
più adeguati. In questo progetto, abbiamo provato tre diversi adiuvanti: l’emulsione 
MF59 - che induce una risposta mista Th1/2 - oppure la combinazione di un 
agonista del Toll-Like Receptor 4 (TLR4a) o del Toll-Like Receptor 7 (TLR7a) con 
idrossido di alluminio – che polarizzano la risposta verso il profilo Th1. Gli 
adiuvanti sono stati valutati per la loro capacità di migliorare le risposte 
immunitarie contro il vaccino TdaP contenente tre antigeni di B. pertussis: tossina 
della pertosse geneticamente detossificata (PT-9K/129G), emoagglutinina 
filamentosa (FHA) e pertactina (69K).  
La rapida induzione di titoli anticorpali e la polarizzazione della qualità della 
risposta immunitaria indotte dagli adiuvanti qui esaminati sostengono pienamente la 
potenzialità di sostituire i sali di alluminio con adiuvanti alternativi che migliorino 
l’immunogenicità di vaccini combinati contenenti aP. 
Conclusioni 
Complessivamente, i risultati raccolti suggeriscono la possibilità di modulare la 
qualità e l'efficacia di un vaccino complesso lavorando sulla componente adiuvante. 
Migliorare la caratterizzazione analitica dei vaccini e indirizzare una polarizzazione 
razionale della risposta immunitaria sono proposte come strategie efficaci da 
perseguire per lo sviluppo dei vaccini combinati della prossima generazione. 
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PREFACE	
 
 
 
 
 
 
 
Vaccines, together with antibiotics, are among the most successful outcomes of 
modern medicine. Regardless of this, people reveal a declining confidence and 
compliance when facing vaccines, probably because these products are not 
considered useful in preventing diseases which are mostly unknown and not 
recognized as life-threatening. People are no longer aware of diseases that vaccines 
protect from as they have never experienced them. As a consequence, vaccination 
coverage decreases, resulting in large outbreaks of highly contagious diseases, as 
recently seen e.g. for measles [1]. Additionally the complexity of vaccine products 
contributes to concerns about vaccine ingredients and unexpected side-effects.  
Vaccine research is a complex field, covering many areas ranging from the 
discovery and evaluation of new antigenic candidates to the continuous 
improvement and validation of products already available in the market.  
During my PhD I have investigated the possibility to improve combination vaccines 
through the application of pharmaceutical sciences approaches directed and 
focusing on adjuvants. I have explored the potential of complete characterization 
and rational design of adjuvants within complex vaccine formulations, with the 
purpose of improving development and awareness of future vaccines - emphasizing 
the importance of adjuvants.  
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CHAPTER	 I . 	 	
GENERAL	 INTRODUCTION	AND	
OBJECTIVE	OF 	THE	THESIS 	
 
 
 
 
 
 
 
VACCINES		
At the end of the nineteenth century Louis Pasteur identified microorganisms as 
agents responsible for infectious diseases. Moreover, by accidentally leaving a 
bacteria culture without nutrients, he observed that it was possible to artificially 
obtain microorganisms showing attenuated virulence and able to confer immunity 
against the disease. Pasteur referred to attenuated bacteria as “vaccines” in honor of 
Edward Jenner’s discovery - dated back at the end of the eighteenth century - about 
the possibility to protect people against smallpox through inoculation with cowpox, 
a less dangerous disease which he denoted as Variolae Vaccinae (from the Latin 
word vacca, cow).  
More than a hundred years after Pasteur’s observation, vaccines are considered a 
fundamental milestone for healthcare providing life-long protection against 
numerous infections. At first the leading principle was the basic one proposed by 
the French microbiologist, starting with the identification of the microorganism, 
inactivation through heat or exsiccation and subsequent injection. A big step 
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forward was made during the 1920s by Gaston Léon Ramon who developed the 
first two vaccines – against Corinebacterium diphtheriae and Clostridium tetanii - 
constituted not by the whole bacterium but only by a part of it. Diphtheria and 
tetanus toxins, identified as the causes of the respective diseases, were inactivated 
with formaldehyde following a procedure similar to the one used in modern vaccine 
manufacture [2].  
A brief historical overview across vaccines discovery and development allow to 
categorize vaccines in three main groups: live-attenuated whole microorganisms, 
heat or chemically inactivated microorganisms, and microorganisms’ subunits [3].	
This classification is still valid in modern vaccinations but technology 
improvements and the continuous raising of safety concerns drive vaccine 
development to limit the use of whole pathogens in favor to the identification and 
isolation of well-characterized components responsible of conferring immunity to 
the disease. Indeed, reversion of toxicity and high levels of reactogenicity with 
subsequent adverse-effects are challenges that might be faced when working with 
whole inactivated microorganisms. Significant improvements in terms of safety 
were introduced by the advent of the recombinant DNA technology which allowed 
the production of recombinant antigens [4].  
 
COMBINATION	VACCINES	
Continuous vaccine development (Figure 1 [5]) is pushing towards the constant 
progress in the development of combination vaccines, which allow providing 
immunity against more than one infectious disease. By incorporating separate 
antigens or individual vaccines into a single product, combination vaccines 
represent an important means of simplifying vaccination strategies. Their 
development started over sixty years ago with the combination of diphtheria toxoid 
(DT), tetanus toxoid (TT) and whole-inactivated pertussis bacteria (wP) into a 
single DTwP vaccine that has become the cornerstone of pediatric and adult 
immunization programs [6]. Over the years the wP component was replaced with 
less reactogenic acellular pertussis (aP) antigens, and further routine vaccines were 
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FIGURE 1. Timeline of vaccine development showing the number of vaccines introduced
in the market every decade (yellow) since the discovery of the first vaccine at the end of
the eighteenth century. In orange the progressive cumulative number of vaccine products is 
recorded.  
1790s: smallpox.  
1880s: rabies, typhoid.  
1890s: cholera, plague.  
1920s: diphtheria, tetanus, pertussis, tuberculosis.  
1930s: yellow fever, influenza, typhus.  
1950s: polio (injected, inactivated).  
1960s: polio (oral, live), measles, mumps, rubella.  
1970s: anthrax, meningococcal disease (polysaccharide), pneumococcal disease
(polysaccharide).  
1980s: adenovirus infection, rabies (cell culture), tick-borne encephalitis, hepatitis B 
(plasma derived), Haemophilus influenza type B infection (polysaccharide), hepatitis B
(yeast or baculovirus, surface antigen), Haemophilus influenza type B infection
(conjugate), typhoid (other variants).  
1990s: cholera (killed whole cell), Japanese encephalitis (inactivated), cholera 
(recombinant toxin B), cholera (live attenuated), typhoid (capsular polysaccharide),
varicella zoster, acellular pertussis, hepatitis A (inactivated), lyme disease, rotavirus
infection, meningococcal disease (conjugate group C).  
2000s: pneumococcal disease (7 valent, conjugate), cold-adapted influenza, meningococcal 
disease (4 valent, conjugate), varicella zoster (live), rotavirus infection (attenuated),
human papilloma virus (4 valent, recombinant), cholera (whole cell), Japanese encephalitis
(Vero cell colture), human papilloma virus (2 valent, recombinant).  
2010s: (current decade): pneumococcal disease (13 valent, conjugate), meningococcal
disease (recombinant group B). 
Data collected from [5]. 
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subsequently added to the DTaP combination following the growing number of 
childhood diseases for which vaccination was recommended.  
The latest advance in DTaP combination vaccine development is defined by 
Infanrix™ -hexa from GSK, which protects against six different diseases by 
carrying diphtheria, tetanus, and acellular pertussis antigens (DTaP) together with 
inactivated polio vaccine (IPV), Haemophilus influenzae vaccine (Hib), and 
hepatitis B vaccine (HepB) [7]. Other significant combination vaccines are the 23-
valent pneumococcal polysaccharide vaccine (Pneumovax 23™ from Merck) [8] or 
the 4-valent meningococcal conjugate vaccine (Menveo™ from Novartis Vaccines) 
[9], which respectively protect solely against pneumococcal and meningococcal 
infections. It is likely that new combination vaccines will reach the market in the 
coming years, combining DTaP-based with pneumococcal or meningococcal 
vaccines. Promisingly, these products are already being co-administered at the same 
vaccination visit, and no major negative effects have been reported [10].	 
Combination vaccines confer several advantages, starting with the simplification of 
the immunization schedule and subsequent reduction of the number of injections 
needed to confer protection against multiple diseases. Benefits can be identified on 
various levels of society, with fever shots and improved compliance for recipients, 
and lower costs, less medical visits needed, better coverage and the possibility to 
more easily add new vaccines into the immunization program for national 
healthcare systems [7]. 
Combining multiple vaccines into a single product potentially introduce some 
challenges since fine-tuning respective immunization schedules which foresee a 
different number of doses on different time points is not immediate (Figure 2). 
Moreover adverse interactions among combined antigens have to be avoided while 
maintaining the final product as safe and immunogenic as the individual vaccine 
components. Improvements in this context may involve the inclusion of adjuvants, 
which can potentially bring advantages, such as increased antigen stability and 
reduced interference among vaccine components, as well as antigen dose reduction 
and reduction of the number of scheduled immunizations [11]. 
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VACCINE	ADJUVANTS	
Adjuvants owe their name to the Latin word adjuvare, meaning “to help”. Ramon, 
previously cited for his studies about diphtheria and tetanus toxins, was the first to 
describe adjuvants as “substances used in combination with a specific antigen that 
produced a more robust immune response than the antigen alone” [12]. In whole 
live attenuated or inactivated vaccines the role of potentiation of the immune 
response is carried out by components naturally present in respective 
microorganisms, such as bacterial DNA or lipopolysaccharide, which are 
recognized as non-self by the host thus generating an immune response. The 
introduction of purified and recombinant antigens caused an evident increase in 
safety profile but, despite that, antigens alone resulted to be less immunogenic and 
not always protective. Therefore, vaccine development becomes a complex fine-
tuning between safety and efficacy of the final product. In this perspective, 
adjuvants were introduced to balance the removal of natural immune-stimulatory 
components of the pathogens with the aim to enhance an immune response similar 
to the one triggered by the natural infection [11-13], while maintaining equilibrium 
between vaccine safety and efficacy. 
Birth 1 mo. 2 mo. 4 mo. 6 mo. 12 mo. 15 mo. 18 mo. 19‐23 mo. 2‐3 yr. 4‐6 yr.
Diphtheria, 
Tetanus, 
Pertussis
DTaP DTaP DTaP DTaP
Measles, 
Mumps, 
Rubella
MMR
Hepatitis B HepB
Heamophilus 
influenzae 
type B
Hib Hib Hib
Pneumococcal PCV PCV PCV
Rotavirus RV RV RV
Inactivated 
Poliovirus
IPV IPV IPV
Varicella Var.
Hepatitis A
Influenza
IPV
Flu (yearly)
MMR
Var.
HepA (2 doses)
Vaccine
Age
HepB HepB
DTaP
Hib
FIGURE 2. Recommended immunization schedule for children aged 0 through 6 years.
Adapted from [7].  
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The inclusion of adjuvants in vaccines provides a number of advantages which 
confer the potential to: 
 Increase antigens immunogenicity; 
 Lower the number of doses needed to confer protection – quicker response; 
 Lower antigen doses with reduced impact on production costs; 
 Modulate quality of the immune response to promote protection; 
 Modulate quantity of the immune response by extending duration and 
potency of induced antibodies; 
 Enable complex vaccine combinations overcoming competition among 
included antigens; 
 Overcome limited immune response in endangered population such as the 
elderly, young children, and immunocompromised people. 
 
For almost 80 years aluminum-based adjuvants - approved in the 1920s - were the 
only adjuvants licensed for human use, followed by MF59 approval for inclusion in 
an influenza vaccine in 1997 [13]. While the main feature of aluminum salts and 
MF59 is the delivery of antigens to immune cells, “second-generation adjuvants” 
have been developed combining a delivery system with an immune-potentiator 
molecule [11]. Among these AS04 [14] combine the lipopolysaccharide analog 
monophosphoryl lipid A (MPLA) with aluminum salts and was the first to be 
approved for inclusion in a vaccine against Hepatitis B virus (Fendrix® from GSK) 
in 2005 [15] and against human papilloma virus (Cervarix® from GSK) in 2007 
[16]. In Table I a list of adjuvants licensed and evaluated in clinical studies is 
presented. However those are only a subset among the variety of adjuvants 
proposed and described in literature, indicating adjuvant development as a slow and 
difficult process, which undergo many challenges mainly from a safety and 
regulatory perspective [11, 17]. 
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A growing number of research groups are directing their attention and investments 
at deepening the knowledge about adjuvants mechanism of action and studying 
adjuvants effect from an immunological point of view. Formulation science is 
focusing on the complexity induced by the addition of adjuvants to the vaccine 
formulation taking into consideration potential effects on product/antigen stability 
and efficacy [18]. A complex set of analytical characterization techniques is usually 
required for a complete characterization of formulated antigens and antigens-
adjuvants interactions further complicate their application [19]. In the next section 
these challenges will be reviewed focusing on aluminum salts adjuvants, which are 
the mostly used adjuvants for human use [20].  
 
 
	
Adjuvant Description Status
Aluminum salts Insoluble aluminum salts (e.g. hydroxides and phosphates); 
extensive safety record; antigens adsorbed to the surface.
Licensed in EU 
and US
MF59 Squalene oil‐in‐water emulsion; extensive safety record; 
antigens not associated with droplets.
Licensed in EU
AS03 Squalene oil‐in‐water emulsion added with the immune‐
potentiator α‐tocopherol; associated with narcolepsy.
Licensed in EU 
and US
AS04 Combination of aluminum adjuvant with the TLR4 agonist 
monophosphoryl lipid A (MPLA), co‐adsorbed. 
Licensed in EU 
and US
AS01 Liposomes composed added with MPLA and QS21. Clinical phase
CAF01 Cationic liposomes.  Clinical phase
Poly I:C Synthetic double stranded oligonucleotide containing 
repeating units of inosine and cytosine (TLR3 agonist).
Clinical phase
IC31 Antimicrobial peptide bound to a TLR9 agonist. Clinical phase
AS02 Co‐mixture of AS03 emulsion adjuvant with MPLA and QS21. Clinical phase
Imiquimod TLR7/8 agonist small molecules immune potentiators  
(SMIP).
Clinical phase
CpG olugonucleotides TLR9 agonists based on bacterial DNA. Clinical phase
SE/SE‐GLA Squalene based emulsion added with the TLR4 agonist GLA. Clinical phase
ISCOMS/ISCOMATRIX Small (40 nm) lipid based adjuvants consisting of 
phospholipids, cholesterol and saponins.
Clinical phase
TABLE I. List of adjuvants licensed or under clinical evaluation for use in humans. 
Adapted from [17]. 
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ALUMINUM	SALTS	ADJUVANTS	
Aluminum-salts based adjuvants have become a reference standard for the 
evaluation of new generation vaccines due to their long history of use. Formerly, 
aluminum salts were commonly used for proteins purification by taking advantage 
of their high absorbent capacity. The discovery of the adjuvant effect of this 
material dates back to 1926 when Alexander Glenny and his colleagues described 
the higher antigenic response of a diphtheria toxoid precipitated in presence of 
aluminum potassium sulfate in comparison to the soluble diphtheria toxoid [21]; a 
discovery that inspired Ramon’s adjuvant definition. During the twentieth century 
aluminum adjuvants have been extensively studied and included in many human 
vaccines against infectious diseases showing good safety profile (e.g. vaccines 
against hepatitis B, Haemophilus influenzae and human papilloma virus). However, 
aluminum salts mechanisms of action as vaccine adjuvants is not yet fully 
understood, despite the role of many immunological components involved in the 
response have been recently elucidated [22]. Among the key concepts to exploit 
aluminum adjuvant potential there is the awareness for some antigens that 
adsorption is of key importance to guarantee vaccines stability and adjuvanticity [18, 
23].  
Two main types of aluminum salts have been identified as adjuvants having 
different chemical and physical compositions that strongly influence antigens 
adsorption profile on their surfaces [22, 24]: 
 Aluminum hydroxide, chemically aluminum oxyhydroxide, has a crystalline 
structure composed of needle-shaped nanoparticles which tends to aggregate 
up to an average diameter of 10 µm. Aluminum hydroxide presents only 
hydroxyl groups on its surface and have a point of zero charge (PZC) of 
11.4 thus being positive charged at the neutral pH used for vaccine 
formulations; 
 Aluminum phosphate, chemically aluminum hydroxyphosphate, has an 
amorphous structure with a mean particles size of 50 nm which form 
irregular aggregates of several microns. Both hydroxyl and phosphate 
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groups cover aluminum phosphate surface with a ratio between the two that 
depends on manufacturing conditions. A PZC between 4.5 and 5.5 confer 
aluminum phosphate a negative charge at neutral pH.  
Characterization of aluminum salts chemico-physical properties is of key 
importance for development of stable vaccines and induction of strong antigen-
specific immune responses. The diverse properties of the two mainly employed 
aluminum salts adjuvants allow the rational choice of the one which most likely 
favors antigens adsorption, according to isoelectric points and chemical-physical 
characteristics. Indeed interactions between antigens and adjuvant surface are 
mainly affected by electrostatic forces, hydrophobic interactions and ligand 
exchange [25, 26]. Through antigen adsorption, aluminum salt adjuvant mainly act 
as a delivery system and promotes retention of antigens at the injection site [27-29] 
thus favoring uptake by immune cells [30, 31] while improving antigens physico-
chemical stability and immunogenicity. Antigen-adjuvant interactions have to be 
optimized and characterized to ensure adsorption and favor the development of 
stable and efficacious vaccines.  
A complex set of analytical techniques is needed to characterize antigens and 
antigen/adjuvant interactions. In particular, the adsorption of the antigen on the 
adjuvant surface is an important parameter to be monitored to control the adjuvant 
role of aluminum salts, along with total content and integrity of antigenic 
components [26, 32]. Many analytical tools commonly applied to monitor proteins 
(e.g. gel electrophoresis, Western blot, and liquid chromatography) cannot be 
applied directly to the vaccine product due to interferences with the adjuvant and 
other formulation excipients. Therefore, characterization of antigens in vaccines 
currently requires their complete recovery from aluminum adjuvanted formulations 
mainly through the use of high salt concentration and surfactants to dislocate 
antigens from the adjuvant surface. This desorption procedure could result in 
incomplete antigen recovery and could compromise the integrity of antigens [23, 
33-35]. After centrifugation, antigens desorbed and released in the aqueous phase 
are recovered and analyzed, nonetheless desorption buffer components could 
interfere with the assays, too (e.g. surfactants impact HPLC methods, and histidine 
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buffers are not suitable for colorimetric assays) [19]. In addition, antigens are 
usually formulated in vaccines at doses significantly lower than the quantification 
limits of the analytical tools currently available, especially when considering 
booster dosages [36].  
Thus the variety of analytical tools currently available for the characterization of 
soluble proteins is counteracted by adjuvant presence and antigen-adjuvant 
interactions which cause the analysis of antigens in formulated vaccines to be an 
enormous challenge [37]. In this perspective, the development of analytical assays 
which allow the characterization of antigen-adjuvant interactions and the 
investigation of their effect on antigens stability and immunogenicity is 
continuously needed. It has been already observed that antigens undergo structural 
changes due to interaction and adsorption to aluminum salts and the resulting 
effects on antigens physico-chemical stability due to changes in their environment 
have only recently started to be investigated [22, 32].  
In the last years a variety of analytical techniques have been set up and improved 
for vaccine characterization without requiring preliminary phase separation 
procedures between antigens and aluminum salts adjuvant. The most commonly 
employed techniques are presented in Table II along with the type of information 
provided, the typical working range, and the specificity. The o-Phthalaldehyde 
(OPA) fluorescent protein assay is extensively used to determine antigen 
concentration while adsorbed to aluminum adjuvant and have a sensitivity (20 - 500 
μg/ml) [38] similar to that of a chemo-luminescent method developed to quantify 
formulated antigens through determination of total nitrogen content [39]. A 
significant increase in terms of sensitivity is observed for assays which work on 
antibody recognition (DAFIA, flow-cytometry, SPR) [40-42]. The availability of 
antigen-specific and well-characterized monoclonal antibodies could allow gaining 
information on antigen identity and integrity through analysis of epitopes critical for 
vaccine immunogenicity, guaranteeing specificity to the assay. Spectroscopic 
methods or thermo-analytical techniques could be instead applied to investigate 
conformational and thermal stability of vaccine antigens while adsorbed on 
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aluminum adjuvants [43-48] and to screen different pH, formulation buffer 
components and stabilizers [49]. 
In order to avoid diminished potency and to ensure the development of high quality 
final products as required in modern vaccinology, a complex set of analytical 
techniques is needed and should be ideally applied since the early stages of research 
to characterize each antigen and antigen/adjuvant interaction. However, due to its 
Method Type of information 
provided 
Working 
range 
Specificity References 
OPA  
(o-Phthalaldehyde 
assay) 
Antigen quantity 20 - 500 µg/mL - [38] 
CLND 
(Chemiluminescent 
Nitrogen Detection) 
Antigen quantity 6.75 - 400 
µg/mL 
- [39] 
DAFIA  
(Direct Alum 
Formulation 
Immunoassay) 
‐ Antigen-specific 
(antibody recognition) 
‐ Antigen quantity, identity, 
integrity 
‐ Direct analysis of 
immunological epitopes  
0.16 - 10 
µg/mL 
+ [40] 
Flow-cytometry ‐ Antigen specific 
(antibody recognition) 
‐ Antigen quantity, identity, 
integrity 
‐ Direct analysis of 
immunological epitopes 
‐ Content uniformity 
6.2 - 200 
µg/mL 
+ [41] 
SPR - Biacore (Surface 
Plasmon Resonance) 
‐ Antigen specific 
(antibody recognition) 
‐ Direct analysis of 
immunological epitopes  
‐ Antigen conformational 
and thermal stability 
20 µg/mL + [42] 
Fluorescence 
spectroscopy 
(Intrinsic/Extrinsic) 
Antigen conformational and 
thermal stability  
50 - 200 µg/mL - [43, 44, 46, 
49] 
Near IR transmittance 
spectroscopy 
Antigen quantity 0 - 1.75 mg/mL - [48] 
FTIR  
(Fourier Transform IR 
spectroscopy) 
Antigen conformational and 
thermal stability 
0.5 - 1 mg/mL - [47] 
DSC  
(Differential Scanning 
Calorimetry) 
Antigen conformational and 
thermal stability 
0.5 - 1 mg/mL - [44, 45] 
TABLE II. List and main features of the analytical methods currently available for 
characterization of vaccine antigens in presence of aluminum-based adjuvants. 
16	
	
complexity, current analytical panel results to be more suitable for proof of concept 
studies and research purposes. In this perspective there is an increasing need for an 
analytical method able to characterize formulated antigens with the sensitivity and 
the specificity typical for antibody-based assays. In particular the specificity should 
be considered as a necessary requirement to overcome the need of separate assays 
for each different vaccine component, which is typically required when working 
with multivalent formulations. 
INTRODUCTION	OF	THE	MODEL	VACCINE:		
ACELLULAR	PERTUSSIS‐CONTAINING	COMBINATION	VACCINES		
The successful approach of combining diphtheria, tetanus and pertussis antigens 
into a single vaccine has become a pillar in pediatric (DTaP) and adults (TdaP) 
immunization programs. Even if vaccination coverage is high, the highly 
contagious respiratory tract infection caused by the Gram negative bacterium 
Bordetella pertussis is still endemic worldwide and the number of cases has been 
increasing over the last years [50-54] suggesting that the current vaccine may not 
provide adequate long-lasting protection against the disease.  
Being among combination vaccines per excellence and jumping into the news for 
worldwide resurgence were among the reasons why acellular pertussis vaccines 
were chosen for the objectives of this thesis and will be discussed in more detail in 
Chapter III. 
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AIM	OF	THE	THESIS		
In this PhD work, formulation science approaches directed on adjuvants were 
applied in order to improve current pertussis combination vaccines.  
The aim was to put in the limelight vaccine characterization on one side and 
rational use of adjuvants to shape the desired immune response on the other, as key 
approaches for the development of improved acellular pertussis combination 
vaccines. Accordingly, the structure of the thesis reflects this vision and is therefore 
organized into two main chapters: 
 Chapter II - Improved in vitro characterization assays for aP combination 
vaccines focusing on the development of improved in vitro characterization 
methods which are required to identify optimal formulation conditions and 
ensure physic-chemical integrity of antigens. Analytical methods currently 
in use commonly require the complete desorption of antigens from 
aluminum-based adjuvants, and are not always able to reveal individual 
antigens in vaccine combinations. The potential of Luminex technology was 
then exploited in an innovative way aiming to develop a multi-plex 
sandwich immunoassay for simultaneous characterization of multiple 
antigens in combination vaccines. The approach to directly analyze antigens 
without physical separation from the adjuvant has been explored with the 
potential to be widely applied to monitor integrity, quantity, and stability of 
antigenic components in aluminum salts formulations. The assay was 
developed for the simultaneous characterization of three acellular pertussis 
antigens when formulated with tetanus and diphtheria toxoids in current 
aluminum hydroxide adjuvanted TdaP vaccines.  
 Chapter III -	 In vivo evaluation of novel adjuvants for improved aP 
combination vaccines pursue the approach to tailor immune responses to B. 
pertussis antigens contained in TdaP combination vaccines. This chapter 
takes its justification on the recent pertussis outbreaks reported in many 
countries, which suggest that the existing vaccine may not provide adequate 
long-lasting protection against the disease. The approach was designed 
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following the hypothesis that the humoral immune response induced by 
aluminum salts – currently included as adjuvants in the vaccine - might not 
be ideal for providing protection. In particular, MF59 emulsion adjuvant and 
the combination of Toll-Like Receptor agonists (TLRa) with aluminum 
hydroxide were rationally chosen as alternative adjuvants, characterized, 
and compared in a mouse model to assess their potential to enhance and 
fine-tune the immune response against TdaP antigens.  
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CHAPTER	 I I . 	 IMPROVED	 IN 	VITRO 	
CHARACTERIZATION	ASSAYS 	 	
FOR	aP 	COMBINATION	VACCINES 	
 
The pharmaceutical industry has a little secret: even as it invents 
futuristic new drugs, its manufacturing techniques lag far behind 
those of potato-chips and laundry-soap makers. 
Wall Street Journal - Sep 3, 2003 
	
	
	
LUMINEX	TECHNOLOGY	
A complex set of analytical characterization techniques is usually needed to both 
qualitatively and quantitatively characterize antigens in vaccine formulations thus 
guaranteeing high quality final products. In this perspective, Luminex technology 
has been exploited with the potential to improve the analytical characterization of 
antigens in vaccine formulations. Through the set-up of solution-phase bead-array 
immunoassays the simultaneous analysis of identity, quantity, and stability of each 
formulated antigen can be potentially achieved, differently from traditional 
analytical methods which require a separate test for each immune response 
constituent. Luminex technology is indeed mainly known for the possibility to 
manage multiple analytes within a single assay run and has become of great impact 
in many biological evaluations.  
The Luminex approach relies on polystyrene micro-particles, commonly called 
“beads”, internally dyed with different intensities of a red and an infrared 
fluorophores. As a consequence it is possible to mix together differently dyed 
beads which can still be identifiable via their unique spectral signature: hence 
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Luminex peculiarities of allowing multiple measurements simultaneously, in the so 
called “multivalent approach”. Beads surface can be variously functionalized, e.g. 
carboxylated, allowing covalent coupling of analytes and bio-analytical reactions 
to take place over them. Inside the Luminex system, beads are lined up by the 
fluidics in a single file and pass through a detection chamber where a red laser 
excites their internal dyes allowing beads identification and a green laser quantifies 
the bio-molecular interaction occurring at the surface of the beads. Software 
analysis sort registered events by side scattering thus events larger or smaller than 
a single microsphere are excluded, as well as aggregated microspheres. The 
simultaneous analysis of multiple analytes offered by this technology appeared to 
be valuable in various fields ranging from clinical research studies for recognition 
and diagnosis of clinical markers [55, 56], to the vaccine field for the qualitative 
and quantitative profiling of immunological responses [57-59].  
In this study Luminex technology was exploited in an innovative way for the 
simultaneous characterization of acellular pertussis (aP) antigens when formulated 
with tetanus toxoid (TT) and diphtheria toxoid (DT) in aluminum hydroxide (AlOH) 
adjuvanted TdaP vaccines. Luminex approach has been explored for the analysis of 
quality, quantity and degree of adsorption of antigenic components in AlOH-based 
formulations (Figure 3) avoiding physical separation procedures from the adjuvant. 
The purpose was to develop an analytical method having the accuracy, sensitivity 
and specificity typical of antibody-based immunoassays and able to fully 
characterize vaccine antigenic components within a single analysis. 
FIGURE 3. Characterization of vaccine antigens typically requires the application of
various analytical tools to gain information on antigens quality, quantity and degree of
adsorption to adjuvant surface. The approach based on Luminex technology has the
potential to provide a complete characterization within a single analysis. 
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In vitro vaccine characterization based on Luminex technology confers many 
advantages:  
 Specificity of the assay – based on antigen-antibody recognition;  
 Simultaneous analysis of multiple antigens, - “multivalent approach”; 
 Potential application on the entire vaccine formulation without 
separation between antigens and adjuvants. 
The approach pursued in this PhD project foresees the application of Luminex 
for vaccine formulation characterization following two opposite layouts 
presented in Figure 4. The indirect assay approach relied on coupling of antigens 
on the surface of beads, and owed its name to the fact that a reduction on the 
fluorescence signal coming from beads through the green detection laser was 
indirectly proportional to an increase of the amount of antigens in vaccine. The 
direct approach rested on an opposite layout in which antibodies were coupled to 
the beads and required to directly recognize antigens in vaccine formulation. 
The two approaches will be reviewed in detail in the following pages. 
	 	
FIGURE 4. Schematic representation of the two opposite layouts investigated for in vitro 
characterization of vaccine antigens using Luminex technology. Indirect assay: antigens 
are covalently coupled to the bead surface and the fluorescent (MFI) signal generated 
result indirectly proportional to the amount of formulated antigens. Direct assay: direct 
quantification of antigens in solution through a capture antibody linked to the bead 
surface, MFI signal result to be proportional to antigens amount. 
Capture/detection 
specific antibody
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INDIRECT	LUMINEX	ASSAY	FOR	ANALYSIS	OF	FORMULATIONS	
The first approach taken into account to investigate the possibility of developing an 
analytical assay based on Luminex technology for vaccine formulations 
characterization relied on coupling of antigens to the surface of magnetic 
carboxylated beads. The underlying assumption (described in Figure 5) considered 
the definition of a calibration curve for antigens quantification through the addition 
of a fixed antibody dilution to known antigen concentrations. As a result only the 
complementary amount of antibodies would not be saturated by the free antigens 
thus being prone to be detected by the respective antigen-coupled beads. The 
quantification of the fluorescence signal associated to beads would then be directly 
proportional to the amount of not-saturated antibody and consequently indirectly 
proportional to the amount of antigens in the sample. The obtained fluorescent 
signal interpolated in the calibration curve provides a quantification of the antigen 
in the analyzed sample. 
Materials and Methods 
Antigens and Adjuvants 
Aluminum hydroxide (AlOH) adjuvant was obtained from Novartis Vaccines 
(NVx, Marburg, Germany) manufacturing while the acellular pertussis antigens 
genetically detoxified pertussis toxoid (PT-9K/129G) [60], filamentous 
hemagglutinin (FHA), and pertactin (69K) were produced by Lonza Group (Basel, 
Switzerland).  
Preparation of adjuvanted formulations 
TdaP antigens were subsequently adsorbed onto 2 mg/mL AlOH suspension 
(correspondent to 0.45 mg/mL Al3+) [24] at the following final concentrations: 
10 Lf/mL TT, 4 Lf/mL DT, 8 μg/mL PT, 8 μg/mL FHA, and 16 μg/mL 69K. 
Formulations were then adjusted by the addition of 10 mM Histidine buffer and 
9 g/l NaCl to the recommended physiological ranges of pH (6.5 ± 0.5) and 
isotonicity (osmolality, 300 ± 60 mOsm/kg). 
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Characterization of antigens stability 
Antigens integrity and stability when formulated with or without AlOH adjuvant in 
formulation buffer or in formulation buffer plus 0.01% (v/v) Tween20 was 
evaluated by Western Blot (WB) [61] and sandwich ELISA (according to internal 
NVx procedures). 
Size and melting temperatures of antigens formulated without AlOH were 
determined with the particle size analyzer Zetasizer NanoZS (Malvern Instruments 
Ltd., Malvern, UK).  
Antibodies 
Monoclonal antibodies (mAb) anti-69K were obtained from Novartis Vaccines 
(NVx, Siena, Italy) manufacturing. Monoclonal antibodies (mAb) anti-PT or 
anti-FHA were produced by Areta International (Varese, Italy). Polyclonal 
FIGURE 5. Layout of the indirect assay: A. serial antigen dilution is incubated with B. a
fixed antibody concentration; C. only not-saturated antibodies will be recognized by
antigen-coupled beads. A calibration curve is obtained (more antigen in solution, less
not-saturated antibodies, less fluorescent signal from beads surface) and is used for
interpolation and quantification of antigens in formulation samples. 
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antibodies (pAb) anti-PT or anti-FHA were obtained through purification (Ab 
SpinTrap, GE Healthcare, Little Chalfont, Buckinghamshire, UK) of sera of 
mice immunized with monovalent antigens formulated with AlOH adjuvant as 
described above. IgG concentration was measured by UV spectrum at 280 nm. 
Phycoerythrin-conjugated anti-mouse secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA; 1:400) was used as 
secondary detection reagent. 
Luminex indirect assay procedure 
Acellular pertussis antigens (PT, FHA, 69K, 20 µg each) were coupled to the 
carboxyl groups of 2.5 x 106 MagPlex microspheres (Luminex Corporation, Austin, 
TX) following manufacturer's instructions. Each antigen was coupled to a 
microsphere set, identifiable through its unique spectral signature.  
Samples were diluted in formulation buffer (10 mM Histidine, 9 g/l NaCl) 
containing 0.01% (v/v) Tween20. Diluted antigens and antibodies were added (10 
µl/well and 50 µl/well respectively) to black, opaque, 96-well flat-bottom plates 
(Bio-plex ProTM, Bio-Rad Laboratories, Inc., Hercules, CA). After a 30 minutes 
incubation step antigen-coupled beads were mixed at 1:5 dilutions in 10 mM 
phosphate buffer (PBS 1X) pH 7.2 containing 0.05% (v/v) Tween20 and were 
added to the samples (10 µl/well). After 30 minutes, phycoerythrin-conjugated 
anti-mouse secondary antibody (1:400) was used for detection in a 15 min 
incubation step. The resulting immune-complexes were resuspended in formulation 
buffer and analyzed on the Luminex LX-200 system. 
After each incubation steps plates were washed with formulation buffer by an 
automatized magnetic washer HydroSpeed 96i (Tecan, Männerdorf, Switzerland). 
All reaction steps were carried out at room temperature, in the dark and under 
agitation motion using a horizontal shaker.  
Data analysis 
The Bio-Plex Manager 5.0 software (Bio-plex ProTM, Bio-Rad Laboratories, Inc., 
Hercules, CA) was used to determine the concentration of antigens as median 
fluorescence intensities (MFI) by using a not-adjuvanted aP formulation as 
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reference. MFI values were plotted against known concentration of the reference 
standard and a five-parameters nonlinear regression (5PL) [62] fitting was used to 
generate a curve and calculate the concentration of unknown samples through the 
equation: Y=d+((a-d)/(1+(X/c)^b)^g) where a, b, c, d, g were the parameters 
describing the curve, Y was the fluorescence reading and X the concentration to be 
determined. 
Results and Discussion 
A Luminex single-plex immunoassay was initially developed to characterize 69K 
antigen in mock formulations, i.e. model formulations in which all the conditions 
(formulation buffer, pH, and ionic strength) are preserved except the presence of 
adjuvant. The 69K antigen showed evidence of precipitation in its buffer what was 
even more evident in mock formulation conditions and working in vaccines 
concentration ranges (8-16 µg/ml). Various set of orthogonal techniques have been 
applied to study this precipitation phenomenon and improved 69K stability was 
achieved by the addition of 0.01% (v/v) Tween20 to the formulation buffer. 
Western blot analysis  
Western blot analysis was performed on 69K formulated with or without AlOH 
adjuvant in formulation buffer or in formulation buffer plus 0.01% (v/v) Tween20. 
FIGURE 6. Western blot analysis showing Tween20 0.01% (v/v) effect on 69K antigen
formulated at 16 µg/ml with or without (Mock) AlOH adjuvant. TCA: formulations
supernatants (SN) treated with Trichloroacetic Acid to precipitate and reveal even low
amounts of not-adsorbed antigens. DES: formulations treated with desorption buffer (KPi
300mM) to allow antigens separation from adjuvant surface. Mock formulations were
analyzed directly or after centrifugation (both SN and resuspended pellet were loaded).
The addition of Tween20 was shown to increase antigen stability. 
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The presence of the surfactant was shown to not impact antigen adsorption profile 
onto AlOH surface. Moreover, Tween20 favored the recovery of 69K in vaccine 
supernatant after centrifugation, suggesting improved antigen stability (Figure 6). 
Sandwich ELISA 
In parallel to Western Blot analysis, sandwich ELISA were performed to 
investigate the effect of Tween20 on the stability of 69K antigen in AlOH or mock 
formulations. Again, antigen adsorption onto AlOH resulted not to be impacted by 
the presence of the surfactant in solution, which instead appeared essential for 
accurate antigen quantification in mock formulations at both the tested 
concentrations (Table III). 
 
Dynamic Light Scattering 
Dynamic Light Scattering (DLS) analysis revealed a remarkable increase in the 
count rate over-time when 69K antigen were analyzed at 16 µg/ml in its buffer or 
in mock formulations, suggesting antigen’s tendency to increasingly aggregate. 
After 6 hours a drop in the count rate was registered, and protein precipitation 
occurred. This trend was reversed by the addition of Tween20 to the formulation 
buffer: when a stable count rate was recorded during the kinetic experiment, with 
TABLE III. Sandwich ELISA results showing Tween20 0.01% (v/v) stabilizing effect on 69K 
antigen formulated at 8 or 16 µg/ml with or without AlOH adjuvant. As expected, 69K is 
adsorbed to AlOH surface thus no antigen is quantified in AlOH supernatants. Accurate antigen 
quantification in mock formulation is obtained only in presence of Tween20.  
N.d.: not defined. LOQ: limit of quantification of the method. 
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only a slight increase occurring after 6 hours. Moreover, a 4°C increase in the 69K 
melting temperature was registered when including Tween20 in the formulation, 
further proving the stabilizing effect of the surfactant (data not shown). 
Gathering up the results provided by the various techniques applied, they all lead to 
the conclusion to include Tween20 surfactant in the formulation buffer as a useful 
tool to stabilize and better characterize antigens when formulated without AlOH. 
Tween20 is a surfactant commonly used in vaccine products (e.g. vaccines against 
Hepatitis A and B [63]) and was shown not to impact antigen adsorption profile 
onto AlOH adjuvant. 
The Luminex immunoassay was then developed and optimized preparing both the 
calibration curve and the samples in formulation buffer containing 0.01% Tween20 
(v/v). Analysis of TdaP vaccines formulated without AlOH adjuvant provided a 
precise 69K quantification at 8 and 16 μg/ml with observed concentrations (Cobs) in 
agreement with nominal amounts (Cexp) within a deviation of ± 10% (Table IV). In 
addition to the previously evaluated techniques, also Luminex approach suggested 
the need of Tween20 inclusion for accurate antigen quantification in mock 
formulations. Moreover, analysis of TdaP vaccines supernatants after vaccine 
centrifugation (10 min, 3500 x g) revealed that 69K adsorption rate onto AlOH 
TABLE IV. Luminex indirect analysis of 69K antigen formulated at 8 or 16 µg/ml with or 
without AlOH adjuvant. Similarly to ELISA results, no antigen is quantified in AlOH 
supernatants, and accurate antigen quantification in mock formulation is obtained only in 
presence of Tween20.  
N.d.: not defined. LOQ: limit of quantification of the method.
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adjuvant surface was almost complete at both the tested concentrations. Outcomes 
obtained from the developed Luminex immunoassay resulted to be consistent and 
fully comparable with those obtained by sandwich ELISA, which is considered a 
reference assay for aP antigens characterization in AlOH adjuvanted vaccines. 
Luminex single-plex indirect assays for PT and FHA were later developed and 
optimized under the same conditions used for 69K antigen. Subsequently 
interference among the three bead sets was investigated to evaluate the feasibility 
to develop a tri-plex assay for the simultaneous detection of the three aP antigens. 
No differences in assay sensitivity and no cross-reactivity were observed among 
the single-plex assays thus confirming the feasibility to develop a unique tri-plex 
assay (Figure 7).  
The ability of the tri-plex assay to characterize acellular pertussis antigens in terms 
of identity and quantity was evaluated on non-adjuvanted mock formulations, and 
once established TdaP vaccines formulated in presence of AlOH were analyzed. 
FIGURE 7. Evaluation of the cross-reactivity of the Luminex tri-plex assay. Different
dilutions of mAb (A) anti-PT, (B) anti-FHA, (C) anti-69K were incubated with a mix of
beads coupled with PT, FHA or 69K antigens. A detectable MFI signal was generated by
each beads set in presence of the related antibody only, thus proving absence of cross-
reactivity among analytes. Dotted lines represent mAbs working dilution, which
corresponds to the concentration of detection antibody that yields 80% of the maximum
obtainable signal (IC80).  
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The simultaneous characterization of the three aP antigens was performed on the 
whole TdaP vaccine in presence of AlOH with or without a preliminary treatment 
of the adjuvant with a saturating molecule to investigate if aspecific interactions of 
assay components with AlOH surface occurred. As expected, the analysis of non-
saturated vaccine samples provided inaccurate quantification of antigens thus 
confirming the aspecific binding hypothesis. On the other hand, AlOH saturation 
with BSA or other saturating agents caused under-quantification of the antigens. 
The assumption, supported also by the observation in Figure 8, relied on a steric 
interference of the saturating molecule in the antigen-antibody recognition 
happening over the AlOH surface. 
In conclusion, the indirect Luminex approach for the characterization of antigens 
was abandoned since in the presence of AlOH adjuvant antigen detection was not 
feasible. Hence the decision to move on with the direct approach was taken, 
relying on the direct antibody recognition, with the potential to work in a lower 
concentration range - thus being less subjected to adjuvant presence.  
	 	
FIGURE 8. Centrifuged AlOH pellet not-saturated compared to pellet saturated in 0.5%
BSA. The effect was interpreted as indication of a steric interference of the saturating
molecule in the antigen-antibody recognition happening over AlOH surface. 
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DIRECT	LUMINEX	ASSAY	FOR	ANALYSIS	OF	FORMULATIONS	
The direct Luminex approach for analysis of vaccine formulations consisted of 
coupling specific antibodies to magnetic carboxylated beads for the recognition of 
related antigens in vaccine formulation (Figure 9). The quantification of the 
fluorescence associated to each type of antibody-coupled bead led to the 
determination of the amount of related antigen in solution. The developed method 
was arranged like a sandwich ELISA but with two major differences: 
 The multiplexing approach, by which multiple antigens could be analyzed 
simultaneously within the same sample by the use of uniquely identified 
fluorescent beads; 
 The solution phase kinetic, which favors the detection of lower amounts of 
analytes compared to planar kinetic immunoassays. 
 
The investigation of the Luminex technology as an improved analytical method for 
vaccine characterization through the application of the direct assay approach 
resulted in a manuscript entitled “Multiplex immunoassay for in vitro 
characterization of acellular pertussis antigens in combination vaccines” which was 
submitted to the Analytical Biochemistry Journal. The manuscript is reported in the 
following pages, describing in detail the procedures leading from assay 
development to acellular pertussis antigens characterization in AlOH adjuvanted 
TdaP vaccines. 
FIGURE 9. Layout of the direct Luminex assay developed for characterization of aP 
antigens in TdaP vaccines adjuvanted with AlOH. Capture antibodies are coupled to 
beads and directly recognize formulated antigens. 
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Abstract 
Vaccines in vitro characterization is required to identify optimal formulation 
conditions to ensure physical, chemical, and biological integrity of antigens and 
adjuvants. Analytical methods currently in use are mostly suitable for the 
characterization of unformulated antigens – thus requiring the complete desorption 
from aluminum-based adjuvants - and are not always able to reveal individual 
antigens in vaccine combinations. Here, Luminex technology is proposed as proof 
of concept for the development of improved analytical method for vaccine 
characterization, based on the use of specific antibodies bound to magnetic 
microspheres presenting unique digital signatures for simultaneous recognition of 
respective antigens in the entire formulation. TdaP (tetanus, diphtheria and pertussis 
antigens adjuvanted with aluminum hydroxide) combination vaccines were chosen 
as model to develop an assay able to quantify acellular pertussis (aP) antigens and 
their levels of adsorption to adjuvant at the same time. This assay was directly 
applicable on the whole vaccine, avoiding any laborious procedure for separation of 
the antigens from the adjuvant. Accurate and reproducible quantification of aP 
antigens in TdaP vaccine has been achieved in a range between 0.78 and 50 ng/mL, 
providing information on antigen identity, quantity, and degree of adsorption to 
aluminum hydroxide. Luminex characterization method has the potential to be 
evaluated as correlate of in vitro potency assays - ideally allowing reducing in vivo 
animal studies. 
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1. Introduction 
Vaccination is an effective and successful medical intervention and vaccines have 
profoundly improved public health globally. Historically, progress in science and 
modern technologies have allowed vaccinology to move from the use of whole 
pathogen-based products to safer purified recombinant antigens, and adjuvants are 
often required to induce proper immune responses and provide adequate protection. 
Also, increasing interest has been shown in developing vaccines able to confer 
immunity against more than one infection by means of a single injection. These 
products are known as combination vaccines and consist of two or more 
immunogens physically combined into a single preparation. The value of 
combination vaccines is supported by the successful approach of combining 
diphtheria, tetanus and pertussis antigens into a single product, which has become 
the cornerstone of pediatric and adult immunization programs [6, 7]. Interestingly, 
pertussis vaccines also exemplify how the replacement of whole-cell antigens (wP) 
with the acellular antigens (aP) can significantly reduce reactogenicity and improve 
safety, paving the way to even more complex combinations (e.g., with inactivated 
polio, Haemophilus influenza and hepatitis B vaccine). In fact, it is expected that 
the need for larger combinations will further increase in future vaccine development, 
which may facilitate the introduction of new vaccines in current immunization 
schedules and simplify vaccination strategies by reducing the number of injections.  
It is evident that, as vaccines move toward advanced adjuvanted combination 
strategies, an increase in product complexity is observed, which poses significant 
challenges for vaccine characterization. In fact, the development of high quality 
final products, as required by modern vaccinology, needs a complex set of 
analytical techniques to characterize each antigen and antigen/adjuvant interaction, 
which should be ideally applied since the early stages of research. For instance, 
when working with insoluble aluminum salt (e.g., aluminum hydroxide, AlOH; 
aluminum phosphate), antigens adsorption has to be monitored as an important 
parameter related to the immune-potentiator role of these adjuvants [26, 32]. 
However, several biochemical and biophysical methods applied to monitor antigens 
(e.g., gel electrophoresis, circular dichroism, liquid chromatography, colorimetric 
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assays) are yet mostly suitable for the characterization of unformulated antigens, 
due to interference with the adjuvant and/or the excipients. For example the 
turbidity caused by aluminum suspension inhibits direct antigen quantification by 
colorimetric assays (e.g., bicinchonic acid or Lowry [64]). Therefore, the need for 
antigens characterization in aluminum-adjuvanted vaccines is currently resolved by 
adjuvant dissolution [65] or by laborious and time-consuming desorption 
procedures, which are not always efficient and, more importantly, could alter 
antigens structure [23, 34, 35]. In this respect, the use of immunoassays, as the 
enzyme-linked immune-sorbent assay (ELISA), has represented a possible 
alternative for antigen quantification. Despite being reproducible and specific, 
ELISA methods require separate settings and analysis for each antigen included in a 
combination vaccine, and may require [66] or not [67] antigen desorption from 
aluminum salts prior quantitation, depending on the conditions. More recently 
antibody-based immunoassay [40] and flow cytometry [41] were also used to 
directly quantify antigens adsorbed onto aluminum adjuvant. However, there is an 
obvious need for methods able to provide information about quantity, identity and 
integrity of multiple formulated antigens along with the accuracy, sensitivity and 
specificity of immunoassays [19].  
In the present study we evaluate the potential of the Luminex technology for 
simultaneous characterization of multiple antigens in a combination vaccine, as 
regard to identity, quantity and degree of adsorption to aluminum hydroxide 
adjuvant. Luminex is a solution-phase bead-array immunoassay, used for the 
analysis of multiple analytes within a single assay run (multi-plex analyses). This 
technology utilizes diverse sets of magnetic microsphere, each containing a 
different color-code (digital signature) and coated with a specific reagent, thus 
allowing the capture and detection of specific analytes from a sample. The analyzer 
can then identify each microsphere particle through the digital signature, and 
quantify the signal related to the captured analytes (e.g., as for classical sandwich 
immunoassays). This method is widely applied in clinical diagnosis and proteomics 
investigations [55, 56], as well as in the vaccine field for monitoring antibody titers 
[57-59]. As model, we here exploit the multi-plex Luminex sandwich immunoassay 
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for characterization of three aP antigens (genetically detoxified pertussis toxin, 
filamentous hemagglutinin, pertactin), when formulated with tetanus toxoid (TT) 
and diphtheria toxoid (DT) in AlOH adjuvanted TdaP vaccines. In fact, Luminex 
could combine ideally the specificity and sensitivity of immunoassays with the 
multi-plex capability required for the characterization of combination vaccines and 
the possibility to avoid laborious desorption procedure from AlOH, due to the use 
of magnetic solid phase and to high sensitivity.  
 
2. Materials and Methods 
2.1 Antigens and Adjuvants 
TT, DT, and AlOH adjuvant were obtained from Novartis Vaccines (NVx, Marburg, 
Germany) manufacturing while the acellular pertussis antigens were produced by 
Lonza Group (Basel, Switzerland): genetically detoxified pertussis toxoid (PT, PT-
9K/129G) [60], filamentous hemagglutinin (FHA) and pertactin (69K). 
2.2 Preparation of adjuvanted formulations 
TdaP antigens were subsequently adsorbed onto 2 mg/mL AlOH suspension 
(correspondent to 0.45 mg/mL Al3+) [24] at the following final concentrations: 10 
Lf/mL TT, 4 Lf/mL DT, 8 μg/mL PT, 8 μg/mL FHA, and 16 μg/mL 69K. 
Formulations were then adjusted by the addition of 10 mM Histidine buffer and 9 
g/l NaCl to the recommended physiological ranges of pH (6.5 ± 0.5) and isotonicity 
(osmolality, 300 ± 60 mOsm/kg).  
2.3 Antibodies 
As capture reagents to be linked to Luminex beads polyclonal antibodies (pAb) 
anti-PT, polyclonal antibodies anti-FHA and a monoclonal antibody (mAb) anti-
69K were used. Polyclonal antibodies anti-PT and anti-FHA were obtained through 
purification (Ab SpinTrap, GE Healthcare, Little Chalfont, Buckinghamshire, UK) 
of sera of mice immunized with monovalent antigens formulated with AlOH 
adjuvant, as described above. IgG concentration was measured by UV spectrometry 
at 280 nm. Anti-69K mAb clone E8D10D3 was obtained from Novartis Vaccines 
(NVx, Siena, Italy) manufacturing. As primary detection reagents polyclonal sera 
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anti-PT, anti-FHA and anti-69K were used. Sera were obtained by immunization of 
rabbits with monovalent antigens formulated with AlOH adjuvant. Animal studies 
were performed in compliance with the Italian law, approved by the local Animal 
Ethics Committee, and authorized by the Italian Ministry of Health.  
Phycoerythrin-conjugated anti-rabbit secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA; 1:400) was then used as 
secondary detection reagent. 
2.4 Assay procedure 
A Luminex tri-plex immunoassay was developed to characterize acellular pertussis 
antigens in TdaP vaccines adjuvanted with AlOH. In detail, 40 µg of pAb anti-PT 
or anti-FHA and 60 µg of mAb anti-69K were coupled to the carboxyl groups of 2.5 
x 106 MagPlex microspheres (Luminex Corporation, Austin, TX), through 
activation via EDC chemistry following manufacturer's instructions.	 Each antibody 
was coupled to a microsphere set, identifiable through its unique spectral signature.  
Samples were diluted in 40 mM phosphate buffer (4X PBS) pH 7.2 containing 
0.01% v/v Tween20 and added (50 µl/well) to black, opaque, 96-well flat-bottom 
plates (Bio-plex ProTM, Bio-Rad Laboratories, Inc., Hercules, CA). Antibody-
coupled beads were mixed at 1:5 dilution in 1X PBS + 0.05% v/v Tween20 and 
were added to the samples (10 µl/well). Samples and beads were incubated for one 
hour. Afterwards, the primary antibodies were diluted (rabbit pAb anti-PT 1:10000, 
anti-FHA 1:6000, anti-69K 1:6000), mixed, and added to wells (50 µl/well). 
Phycoerythrin-conjugated anti-rabbit secondary antibody (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA; 1:400) was then used for 
detection in a 15 min incubation step. The resulting immune-complexes were 
resuspended in 1X PBS pH 7.2 and analyzed on the Luminex LX-200 system. All 
reaction steps were carried out at room temperature, in the dark and under agitation 
motion using a horizontal shaker; after each incubation step, plates were washed in 
1X PBS by an automatized magnetic washer HydroSpeed 96i (Tecan, Männerdorf, 
Switzerland). 
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2.5 Data analysis 
The Bio-Plex Manager 5.0 software (Bio-plex ProTM, Bio-Rad Laboratories, Inc., 
Hercules, CA) was used to determine the concentration of antigens from median 
fluorescence intensities (MFI) by using a not-adjuvanted aP formulation as 
reference. MFI values were plotted against known concentration of the reference 
standard and a five-parameters nonlinear regression (5PL) [62] fitting was used to 
generate the curve and calculate the concentration of unknown samples through the 
equation: Y=d+((a-d)/(1+(X/c)^b)^g) where a, b, c, d, g were the parameters 
describing the curve, Y was the fluorescence reading and X the concentration to be 
determined. 
2.6 Assay qualification 
Repeatability of the assay was assessed by determination of intra-assay variation of 
eleven tri-plex assays performed in different days under the same operating 
conditions. Results were expressed as mean percentage coefficient of variation 
(%CV). Indication on assay sensitivity was obtained through the analysis of 
individual blank wells (n = 80) consisting of sample diluent. The detection limit 
(DL) and the quantification limit (QL) were calculated for each analyte and 
expressed respectively as DL = 3.3/S and QL = 10/S where  is the standard 
deviation of the MFI responses of blank samples and S is the slope of the 
calibration curve.  
Spike recovery studies were performed adding a known amount of aP antigens to 
supernatants of centrifuged AlOH-containing vaccines (10 min, 3500 x g), thus 
gaining indication on assay accuracy. Spike values were expressed as percentages 
of aP antigens doses in TdaP vaccine: 1% spike corresponded to 80 ng/mL PT, 80 
ng/mL FHA, 160 ng/mL 69K; 10% spike corresponded to 800 ng/mL PT, 800 
ng/mL FHA, 1600 ng/mL 69K; and 100% spike corresponded to 8 µg/mL PT, 8 
µg/mL FHA, 16 µg/mL 69K. 
Specificity of the assay was evaluated through evaluation of the potential cross-
reactivity of the tri-plex assay, defined as the ability of an antibody to react with 
similar antigenic sites in different proteins, thus providing non-specific responses. 
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Experiments were arranged to compare MFI generated by each specific assay in 
presence of the relative antigen at 0.78 ng/mL or of the two non-related antigens in 
combination (50 ng/mL each). 
Inhibition experiments were performed to gain additional information on assay 
specificity. In detail, individual aP antigens in their own buffer (bulk) were diluted 
at concentrations ranging from 1.56 to 200 ng/mL and incubated in presence or in 
absence (absence of inhibition) of fixed concentrations of capture antibodies anti-
PT (4 ng/mL), anti-FHA (2 ng/mL), and anti-69K (1.2 ng/mL) singularly or mixed 
together. Remaining non saturated antigens were then quantified by the tri-plex 
assay. 
2.7 Assay application to TdaP vaccines 
Assay application to TdaP vaccines followed three different procedures – illustrated 
in Figure 5 - to gain a complete perspective of the state of antigens in the vaccine. 
(A) After vaccine centrifugation (10 min, 3500 x g) formulation supernatants were 
recovered and directly analyzed; (B) Entire TdaP vaccine formulation was linearly 
diluted in PBS 4X + 0.01% v/v Tween20 to reach a concentration range for aP 
antigens between 50 and 0.78 ng/mL, and directly analyzed in presence of AlOH 
adjuvant; (C) TdaP vaccine was linearly diluted as described in procedure B, 
samples from each dilution step were then centrifuged (10 min, 3500 x g) to allow 
AlOH separation and supernatants were recovered for the analysis. The 80 
< %(Cobs/Cexp) < 120 range for acceptability of antigens quantification was used. 
2.8 Statistics 
Statistical analysis was performed by the use of Graph Pad Prism 5.0 software 
(GraphPad Software Inc, San Diego, CA). Calibration curves were interpolated with 
a 5PL non-linear regression model. Comparison between single-plex and tri-plex 
methods was based both on a Deming regression study followed by evaluation of 
correlation coefficients using Pearson method. Significant differences (p ≤ 0.05) 
among groups in cross reactivity experiments were ascertained using the two-tailed 
t test at the 95% confidence interval, while inhibition experiments were evaluated 
through ANOVA analysis followed by Bonferroni test of significance at the 95% 
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confidence interval. Linearity of the analytical procedure in the identified working 
range was evaluated by linear regression among data points.	 
FIGURE 10. Calibration curves of a) mono-plex assays and b) tri-plex assay used to determine 
antigens concentration from median fluorescence intensities. Mean fluorescence values 
associated to each concentration are shown together with 95% confidence interval. Curves are 
fitted with a 5-PL nonlinear regression model (continuous connecting line), 95% confidence 
bands associated to the fitting are represented by the dots. Parameters describing 5-PL tri-plex 
curves: PT (d = 542.1, a = 23264.2, c = 0.57, g = 3.65, b = -0.61), FHA (d = 226.7, a = 25437.7, c 
= 109.2, g = 0.6, b = -1.5), 69K (d = 61.2, a = 25236.7, c = 54.7, g = 0.46, b = -2.1). 
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3. Results  
The feasibility of Luminex technology for characterization of aP antigens was first 
tested by creating individual single-plex sandwich immunoassays for each of the 
three aP antigens. Three different digital signatures regions of magnetic beads (i.e., 
MC10033, MC10036, MC10039) were used for PT, FHA, and 69K, respectively. 
The 5PL nonlinear regression models were chosen to generate calibration curves for 
extrapolation of concentration values from MFI readings, as these models are 
commonly used to fit immunoassay or bioassay data [62].  
As capture reagents, mouse pAb anti-PT, pAb anti-FHA and mAb-anti69K were 
selected and coupled to the respective Luminex beads, whereas rabbit polyclonal 
sera anti-PT, anti-FHA and anti-69K were used as detection reagents. Bulk aP 
antigens were then individually tested in the single-plex immunoassays at the 
concentrations present in TdaP vaccine (i.e., 8 μg/mL PT, 8 μg/mL FHA, and 16 
μg/mL 69K). Since the used bulk antigens may present physical instability when 
formulated at the vaccine concentrations in absence of adjuvant (not shown), 0.01% 
v/v Tween20 (a surfactant commonly used in vaccine products [63]) was added to 
prevent precipitation events. Three independent calibration curves were generated 
in the concentration range 0.1 - 800 ng/mL for each individual aP antigen (Figure 
10a). The working range of each single-plex assay was identified between 0.78 and 
50 ng/mL since in this range the analytical procedure provided appropriate accuracy 
(deviation of ± 20% between Cobs and Cexp) and linearity (R2 > 0.89).  
We thus analyzed if multiplex conditions, i.e. the simultaneous detection of the 
three antigens (and thus of three bead sets), could lead to possible interference. To 
this aim, a sample containing the three antigens in assay buffer at 800 ng/mL was 
serially diluted 1:1 (v/v, with 4X PBS buffer) till 0.1 ng/mL and analyzed. As 
shown in Figure 10b, curves obtained under the tri-plex assay configuration were 
properly fitted into the 5-PL nonlinear regression model for each antigen (R2 = 
0.877, 0.929, 0.962, for PT, FHA and 69K, respectively), indicating that no major 
interference were occurring. Importantly, comparison of the MFI of the single-plex 
assays with those of the tri-plex assay through Deming regression model and the 
Pearson correlation coefficients (Figure 11) showed good correlation (PT = 0.9930, 
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FHA = 1.000, 69K = 0.9930). The confirmation that the two assay configurations 
(single-plex and tri-plex) lead to comparable results prompted us to further evaluate 
additional assay parameters.  
3.1 Assay qualification  
The repeatability of the tri-plex assay was determined through inter-assay variation 
data, calculated in the 0.78 - 50 ng/mL working range of eleven independent 
standard curves. Values of mean percentage coefficients of variation (Table V) 
resulted below 15% for all the concentrations considered and for all three antigens, 
thus showing repeatability of the multi-plex immunoassay [68]. 
The sensitivity of the tri-plex assay was assessed through the collection of MFI 
values of 80 blank wells analyzed in independent experiments. Detection limits (DL) 
and quantification limits (QL) were calculated as MFI values. QL were converted in 
concentration through data interpolation in the relative 5-PL calibration curve, 
FIGURE 11. MFI generated by single-plex and tri-plex assays were compared through the 
Deming regression model obtaining the following best fit values: PT slope 1.002 ± 0.04109, 
y-intercept when x=0 -1164 ± 854.7; FHA slope 0.9286 ± 0.02081, y-intercept when x=0 -
509.1 ± 352.0; 69K slope 0.9322 ± 0.02494, y-intercept when x=0 -569.1 ± 470.1. 
Comparability of single-plex and tri-plex assays was further confirmed by Pearson 
correlation which provided these correlation coefficients: PT r = 0.9917, FHA r = 0.9975, 
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while DL (in MFI values) were lower than the lowest values of the respective 
curves (Table VI). Spike recovery studies were performed by adding to AlOH-
adjuvanted vaccine supernatants known concentrations of aP antigens, 
corresponding to 1%, 10% or 100% of the vaccine doses. Results are listed in Table 
VII and showed a spike recovery equal or higher than 80% for all the condition 
tested, thus establishing assay accuracy across the specified range.  
To assess the specificity of the tri-plex assay, cross-reactivity experiments were 
then conducted. To this aim, the MFI values were measured for each bead set in 
presence of the lowest concentration (0.78 ng/mL) of the related antigen and 
compared to the MFI signals measured in presence of the highest concentration (50 
ng/mL) of both the other non-related antigens. For example, the signal obtained 
TABLE VI. Detection limit (DL) and quantification limit (QL) for each aP antigen expressed 
as DL = 3.3/S and QL = 10/S, where S is the slope of the calibration curve and  is the 
standard deviation of the responses of blank samples. (n.a., not available, MFI lower than the 
lowest point of calibration curve).
   PT FHA 69K 
 MFI ng/ml MFI ng/ml MFI ng/ml 
DL 320.6 n.a. 162.2 n.a. 36.7 n.a. 
QL 971.5 0.188 491.5 0.691 111.3 0.087 
TABLE V. Assay repeatability expressed as mean percentage coefficient of variation (% CV) 
of eleven tri-plex assays performed under the same operating conditions.	
 
ng/ml 
% CV 
PT FHA 69K 
0.78 3 13 3 
1.56 5 7 5 
3.13 5 6 3 
6.25 10 4 4 
12.5 9 3 2 
25 7 3 3 
50 14 3 8 
TABLE VII. Assay accuracy reported as percent spike recovery of known amounts of aP 
antigens added to AlOH-adjuvanted vaccine supernatants: % aP are referred to % of PT, FHA, 
or 69K antigens doses in TdaP vaccine (1% correspond to 80-80-160 ng/ml; 10% correspond 
to 800-800-1600 ng/ml; 100% correspond to 8-8-16 µg/ml). 
  % aP % spike recovery PT FHA 69K 
1 95.7 98.8 80.4 
10 80.2 80.7 80.0 
100 80.4 86.2 85.6 
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with beads recognizing PT in presence of 0.78 ng/mL PT was compared with the 
signal generated in presence of 50 ng/mL of FHA plus 50 ng/mL 69K.  As shown in 
Figure 12, the non-specific signal with high concentrations of unrelated antigens 
resulted in every case significantly lower than the signal generated by the lowest 
concentration of related antigen (0.78 ng/mL). To further evaluate specificity, 
inhibition experiments were also performed, meaning that the Luminex experiment 
was started after preincubation of each aP antigen with the respective capture 
antibody (as single or in mixture with the other two capture antibodies), resulting in 
MFI inhibition, as expected. On the contrary, a response similar to the one obtained 
without inhibition was found when using non-related antibodies, thus confirming 
tri-plex assay ability to provide information on antigens identity (Figure 13). 
Moreover, after exposure to a thermal stress (e.g., overnight incubation at a 
temperature superior than antigens melting point) antigens were no more properly 
recognized and quantified by the related antibody (data not shown).  
3.2 Assay application to TdaP combination vaccine 
As following step, tri-plex assay was applied to whole TdaP vaccine, to verify the 
possibility to use it for characterization purposes. The TdaP vaccines were assayed 
at linear dilutions from 50 to 0.78 ng/mL of aP antigens. To evaluate the accuracy 
M
FI
PT (ng/ml) 0.78 0
FHA (ng/ml) 0 50
69K (ng/ml) 0 50
M
FI
PT (ng/ml) 0 50
FHA (ng/ml) 0.78 0
69K (ng/ml) 0 50
0
100
200
300
400
500
-69K assay
PT (ng/ml) 0 50
FHA (ng/ml) 0 50
69K (ng/ml) 0.78 0
***
FIGURE 12. Specificity of the tri-plex assay was assessed through analysis of cross-reactivity. 
MFI signals generated by each bead of the tri-plex assay in presence of the related antigen at 0.78 
ng/ml - the lowest concentration in assay working range – were reported in black. Cross-
reactivity fluorescence (grey bars) derived from beads which recognize the corresponding non-
related antigens both at 50 ng/ml - the highest concentration at which antigens are analyzed.  
** p< 0.01, *** p< 0.005 
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of calibration curves in quantifying antigens, control samples formulated at known 
concentrations and in the absence of AlOH adjuvant were added to the experiments. 
Samples containing AlOH only were also included in the analysis to explore the 
risk of artificial fluorescence readouts. However, no evidence of indirect binding of 
reagents used in the assay to AlOH surface was found (data not shown). 
Assay application on TdaP vaccines followed three different procedures - illustrated 
in Figure 14 - to gain a complete perspective of the state of antigens in the vaccine: 
A. analysis of antigens in vaccine supernatant, to evaluate the amount of non-
adsorbed antigens; B. analysis of antigens in TdaP vaccine adjuvanted with AlOH, 
to evaluate total antigen amount; C. analysis of vaccine supernatants after vaccine 
dilution and AlOH separation, to evaluate antigen desorption from AlOH occurring 
during dilution. 
Interestingly, although aP antigens resulted almost completely adsorbed to AlOH 
adjuvant, the high sensitivity of Luminex assay allowed the detection and the 
quantification of very low amounts of not-adsorbed antigens. In fact, these values, 
calculated as percent ratio between the amount of non-adsorbed proteins and the 
total amount of formulated protein in several independent assays, were found to be 
0.40 ± 0.10 % for PT, 0.18 ± 0.05 % for FHA and 0.16 ± 0.09 % for 69K. Efficient 
FIGURE 13. Linear dilutions of individual aP antigens were incubated in presence or in absence 
(no inhibition) of fixed concentrations of capture antibodies pAb α-PT, pAb α-FHA, mAb α-69K 
singularly or mixed together. MFI reduction was observed for each aP antigen when incubated 
with the respective capture antibody or with a mixture of the three capture antibodies. On the 
contrary, a response similar to the one obtained without inhibition was found when using non-
related antibodies, thus confirming specificity of the tri-plex assay.  
Statistical significance (*** p< 0.05) was calculated through ANOVA analysis followed by 
Bonferroni test using no inhibition as controls groups. 
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adsorption to AlOH was expected since the experimental isoelectric points of aP 
antigens (PT = 5-6 or 8.6-9 depending on the subunit, FHA = 6.7-7.7, 69K = 5.9-6.1) 
were compatible with the one of AlOH (pI = 11) when formulation pH was adjusted 
to the physiological range. Moreover, the results obtained were in agreement with 
the qualitative information obtained analyzing vaccine supernatants by Western blot 
analysis in which no antigens were detected (data not shown). 
Quantification of antigens in TdaP vaccines in presence of AlOH adjuvant was 
performed by the analysis of six linear dilution steps of the whole vaccine, which 
resulted in observed antigens concentrations (Cobs) in agreement with nominal 
amounts (Cexp) with a deviation of ± 20%, indicating assay linearity (Figure 15). 
The only measure showing a deviation higher than 20% was recorded when 
analyzing PT at 25 ng/mL, likely related to the fact that this concentration is close 
to the upper plateau of PT calibration curve, where linearity is poorly satisfied 
(Figure 10). Assay performance for aP antigens quantification in TdaP vaccines 
adjuvanted with AlOH was also compared to the quantification of not-adjuvanted 
FIGURE 14. Assay application to TdaP vaccines followed three different procedures to gain a 
complete perspective of the state of antigens in the vaccine. A. analysis of non-adsorbed antigens 
in formulation supernatants after vaccine centrifugation; B. analysis of antigens in whole TdaP 
vaccine formulation linearly diluted and directly analyzed in presence of AlOH adjuvant; C. TdaP 
vaccine linearly diluted (as described in procedure B.) and centrifuged to allow AlOH separation 
and recovery of supernatants which were analyzed to evaluate the influence of experimental 
conditions on antigens adsorption to AlOH surface. 
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aP antigens in combination or not with TT and DT toxoids (mock formulations). As 
shown in Figure 13, assay specificity was confirmed under these conditions 
resulting in unequivocally assessment of the analytes, also in presence of potentially 
interfering vaccine components, such as AlOH adjuvant or other antigens.  
Finally, the influence of experimental conditions on antigens adsorption to AlOH 
surface was evaluated by diluting TdaP vaccine in assay buffer, and analyzing 
vaccine supernatants after centrifugation. As shown in Figure 16, data indicated that 
aP antigens underwent a spontaneous desorption from AlOH surface during dilution, 
FIGURE 15. Analysis of PT, FHA, and 69K antigens in whole TdaP vaccine in presence of 
AlOH adjuvant (dark red) performed at six linear dilution steps of the vaccine. Analysis of aP 
antigens in TdaP mock (orange) and in aP mock (yellow) formulated without adjuvant was added 
to evaluate assay ability to unequivocally quantify aP antigens also in presence of potentially 
interfering vaccine components. The highlighted region indicates the accepted range for 
quantification (80 < %(Cobs/Cexp) < 120). Quantification of PT at 25 ng/ml showed a deviation 
higher than 20% which is related to the fact that this concentration is close to the upper plateau of 
PT calibration curve. 
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probably due to the high concentration of the phosphate buffer used. Notably, while 
the quantification of PT and 69K antigens in the centrifuged diluted samples was 
complete, almost 40% of FHA resulted to be still bound to adjuvant particles 
(Figure 16). Nevertheless, this did not impact the overall antigens quantification in 
TdaP vaccine, which was achieved only by diluting TdaP vaccine in phosphate 
buffer. 
 
 
FIGURE 16. Analysis of PT, FHA, and 69K antigens recovered in supernatants after TdaP 
vaccine linear dilution and centrifugation. Supernatants analysis was performed to evaluate the 
influence of experimental conditions on antigens adsorption to AlOH surface: PT and 69K 
quantification in centrifuged diluted samples was complete while FHA appeared to be still 
partially bound to AlOH particles. The highlighted region indicates the accepted range for 
quantification (80 < %(Cobs/Cexp) < 120). 
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4. Discussion 
In this work the potential of Luminex technology to develop a multi-plex 
microsphere-based immunoassay for simultaneous analysis of acellular pertussis 
antigens (PT, FHA, 69K) in AlOH adjuvanted TdaP vaccines was exploited. 
Luminex technology is currently applied in various fields ranging from genetic 
disease diagnostic [69, 70] to bio surveillance [71, 72]. To the best of our 
knowledge, this is the first reported application for multi-target characterization of 
antigens in a complex vaccine formulation, such as the adjuvanted trivalent TdaP 
vaccine.   
Since the assay relies on antibody recognition and fluorescence detection, it 
combines both the specificity and the sensitivity required for antigen 
characterization in the final vaccine formulation. Particularly, the assay specifically 
determines identity and quantity of antigens without laborious procedure for 
physical separation from AlOH adjuvant, thus preventing protein loss and structure 
alterations such as damage of critical epitopes by exposure to stringent experimental 
conditions required for desorption processes [23, 34, 35]. In fact, the simultaneous 
characterization of the three aP antigens was performed directly on the whole TdaP 
vaccine containing AlOH without any preliminary treatment of the adjuvant. 
Previous works reported that detection antibodies have the tendency to non-
specifically adsorb to AlOH [40, 41] mainly through ligand exchange mechanisms 
and electrostatic interactions [73]. Despite that, no evidence of indirect binding to 
AlOH of the reagents used leading to unspecific signals was found in the Luminex 
assay, and analysis of adjuvant led to fluorescence readouts comparable to blank 
thus confirming assay specificity. 
The analytical procedure reported here was developed as proof of concept for 
possible use of Luminex technology for vaccine characterization purposes, and thus 
to identify possible advantages and/or drawbacks to support early R&D application. 
In fact, the analysis of the current immunoassay for GLP-compliant pre-clinical 
safety study or for clinical purposes would require a full-validation process and in 
depth characterization of the reagent used [74]. For example, polyclonal antibodies 
were used as capture reagents in this work and additional analyses should be 
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addressed to appropriately select monoclonal antibodies capable to recognize 
antigen epitopes critical for vaccine immunogenicity. This would indeed have the 
potential to test vaccine quality and consistency among batches, potentially 
allowing correlations with the clinical efficacy of the product, which is commonly 
evaluated through in vivo potency test in animal models. It is notably that 
quantification of antigen content as a surrogate of potency has already been applied 
for viral vaccines [75-79] with the aim to find a close correlation between antigen 
amount, degree of adsorption to adjuvant and efficacy of the final product. The 
current study could then be considered as a model to further set up in vitro potency 
assays thus supporting the replacement of animal tests accordingly to the 3Rs 
concept (Refinement, Reduction and Replacement of animal testing) [80]. 
Nevertheless, we addressed a number of typical steps and parameters required for 
pre-validation analysis, in order to evaluate actual feasibility and possible 
challenges. Importantly, the method has proved to work in the multi-plex 
configuration with good specificity, accuracy and linearity, in a range between 0.78 
and 50 ng/mL, which indeed allows simultaneous aP antigen characterization in a 
single raw of linear dilution of vaccine. Moreover, the Luminex method presented 
here provides a substantial improvement in terms of sensitivity as compared with 
other commonly used immunoassays [81, 82], which is achieved through antibody 
recognition, generation of a high resolution fluorescent signal and solution phase 
kinetics. In fact, sensitivity is often a critical parameter for vaccine characterization 
methods, since antigens are usually formulated in vaccines at significantly lower 
concentrations than those measurable with currently available analytical tools, 
especially when considering booster dosages [36]. For example, the o-
Phthalaldehyde (OPA) fluorescent protein assay is extensively used to determine 
protein content in vaccine formulations with a moderate sensitivity (20 - 500 
μg/mL), but it lacks specificity when multiple antigens are present in the samples 
[38, 83]. Recently, a chemo-luminescent method with similar sensitivity and 
specificity has been developed to quantify alum-adsorbed vaccine antigens through 
determination of total nitrogen content [39]. Importantly, the high sensitivity of the 
Luminex tri-plex assay allowed precise quantification of low amounts of antigens in 
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formulation supernatants after AlOH separation via vaccine centrifugation. 
Antigens adsorption on AlOH adjuvant surface is yet considered a very important 
parameter for the function of this adjuvant [26, 32] (e.g., WHO recommends 
adsorption values equal or greater than 80% for DT and TT [84]).  
Additional analysis performed on centrifuged aliquots of TdaP vaccine after 
formulation dilution in assay buffer led to the conclusion that antigens undergo a 
spontaneous desorption from AlOH surface during the experimental procedure. 
Since antigens adsorption to AlOH is strongly influenced by pH, ionic strength, and 
presence of anions such as phosphate [85], it is reasonable that phosphate ions 
contained in assay buffer compete with proteins for AlOH binding [86]. While 
complete desorption from AlOH was observed for PT and 69K antigens, only 
partial recovery of FHA was possible in formulation supernatants, which could 
probably be related to its filamentous and repetitive structure[87, 88] and thus to 
stronger binding to AlOH. Nevertheless, quantification of antigen in the total 
formulation was confirmed to be accurate, essentially showing that a common 
characterization protocol including analysis of full vaccine formulation after linear 
dilution and of supernatant would allow concomitant detection of total amount of 
antigens and of percentage of adjuvant adsorption, respectively, through a simple 
workflow (A and B in Fig. 12), and in an individual assay format.   
Taking together, a novel vaccine characterization method through the application of 
Luminex technology is here presented, with possible application in early research 
and potential for consideration in future development and validation processes. 
Importantly, this method could represent a significant improvement for the in vitro 
characterization of complex AlOH-adjuvanted vaccines because providing - in a 
single experiment - information on antigen identity, quantity, and degree of 
adsorption to adjuvant surface of each immunogen included in a multivalent 
combination. In principle, its use may also find application for larger vaccine 
combinations and in presence of other adjuvants and delivery systems such as 
emulsions and polymeric particles, and experiments are ongoing to evaluate this 
possibility. In conclusion, this novel application of Luminex technology may 
overcome certain challenges typically experienced with the available techniques for 
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antigens characterization, like sensitivity issues, laborious and potentially critical 
procedures for antigen desorption from AlOH and simultaneous detection of 
different antigens, with further potential for future development. 
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SUPPLEMENTARY	DATA		
	
ANTIGENS	PRECIPITATION	UPON	CENTRIFUGATION	
As previously described, accurate and reproducible quantification of aP antigens in 
TdaP vaccine has been achieved by the application of Luminex technology for the 
characterization of TdaP vaccine formulations. Through direct antibody recognition 
the developed assay provided information on antigen identity, quantity, and degree 
of adsorption to adjuvant surface.  
Among various scientific questions concerning in vitro vaccine characterization, 
one of the major concerns for formulation scientists is the determination of protein 
structure and stability in presence of an adjuvant. What happens to antigenic 
structures when adsorbed to AlOH has been rarely characterized since this 
information is not easily accessible due to the turbidity of the vaccine formulation 
and adjuvant interference with many available analytical techniques. Another 
challenge is the evaluation of the degree of adsorption of antigens to AlOH surface. 
Usually if no antigen is recovered in the supernatant after vaccine centrifugation, 
AlOH adjuvant adsorption is assumed. However, co-precipitation of antigens with 
AlOH particles cannot be excluded. In this study, preliminary analysis of mock 
FIGURE 17. Analysis of PT, FHA, and 69K antigens formulated in mock TdaP vaccines (without 
AlOH adjuvant). Analysis was performed on five linear dilution steps of the mock vaccine (left) 
or of the supernatant of the mock vaccine recovered after centrifugation. Supernatant analysis was 
performed to evaluate antigens stability in formulation conditions when not adsorbed to AlOH 
surface. The highlighted region indicates the accepted range for quantification (80 < 
%(Cobs/Cexp) < 120). 
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formulations subjected or not to a centrifugation step was performed to evaluate 
protein precipitation in formulation conditions, with the conclusion that 
centrifugation per se does not have an impact on the antigen stability when 
formulated in absence of AlOH adjuvant (Figure 17). Despite that, phenomena 
observed in mock experimental conditions may not represent a real case in presence 
of the adjuvant, and antigens co-precipitation with AlOH upon centrifugation 
cannot be excluded yet remaining an un-resolved technical challenge.  
	
FIGURE 18. Analysis of PT, FHA, and 69K antigens after overnight exposure to different 
temperatures: 4, 25, 37, 60, 90 °C. Analysis was performed on six linear dilution steps of the 
stressed antigens mixed together to preliminary investigate the abilty of capture and detection 
antibodies used in the assay to recognize damaged antigen epitopes. The highlighted region 
indicates the accepted range for quantification (80 < %(Cobs/Cexp) < 120). 
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INTEGRITY	OF	ANTIGENS	
Individual acellular pertussis bulk antigens (in their buffer) were exposed overnight 
to different temperatures (4, 25, 37, 60 and 90 °C) and analyzed for the ability of 
antibodies to still recognize antigen epitopes. 
The analysis proved that the developed analytical method was suitable to provide 
information about antigens integrity and stability. While increasing the temperature, 
observed antigen concentrations (Cobs) resulted less in agreement with nominal 
amounts (Cexp) (Figure 18). The highlighted regions in the graphs correspond to the 
selected acceptable range for antigen quantification 80 < %(Cobs/Cexp) < 120. After 
an overnight incubation at 60 or 90 °C, no points fit into respective regions any 
longer, and none of the three antigens was properly quantified confirming that 
antigens conformational changes could be assessed by this assay. Differential 
scanning fluorescence (DSF) experiments performed by Novartis Vaccines 
colleagues provided melting temperatures (Tm) of the antigens which resulted in 
agreement with the qualitative information obtained using Luminex (data not 
shown). In fact PT unfolding was identified as a multiple-transition process at 60, 
72, and 85 °C, while FHA presented a single Tm at 45 °C. 69K was confirmed to be 
the most stable antigen showing a slight transition at 65 °C followed by a more 
marked structural rearrangement at 81 °C. 
The ability of the antibodies used in this assay to recognize damaged antigen 
epitopes could be exploited in forced degradation studies - an essential step in 
vaccine formulation development - for the identification of potential vaccine 
stabilizers [89]. Additional work should be addressed to replace capture antibodies 
currently used in the assay with appropriately selected and characterized 
monoclonal antibodies capable to recognize antigen epitopes critical for vaccine 
immunogenicity.		
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APPLICATION	ON	MF59	ADJUVANT	
The potential of the developed Luminex-based assay to be applied for 
characterization of vaccines in presence of different adjuvants was discussed in the 
previously reported manuscript and is here further investigated for the MF59 
adjuvant. The MF59 oil-in-water (o/w) emulsion was licensed in 1997, being the 
first alternative adjuvant approved for human use after aluminum salts. The oil used 
in MF59 is squalene which is emulsified - involving the non-ionic surfactants 
Tween80 and Span85 - and then processed with a microfluidizer. The final o/w 
emulsion is stable and composed of oil droplets uniformly distributed at 160 nm 
[13].  
In vitro characterization of vaccines adjuvanted with an emulsion normally requires 
separation of oil phase from the aqueous phase by high speed centrifugation. 
However oil droplets – even the little amount left after phase separation - might 
interfere with routine analytical procedures causing light scattering phenomena. In 
addition, the milky aspect of MF59 is not favorable when working with techniques 
based on light absorbance [34].   
Since Luminex technology conceives an event as “positive” only if recognized both 
by the red and the green detection lasers, this investigation relied on the hypothesis 
that oil droplets would not be registered and would pass undetected through the 
FIGURE 19. Analysis of PT, FHA, and 69K antigens in TdaP vaccine adjuvanted with MF59. 
Analysis was performed at six linear dilution steps of the vaccine in presence of the emulsion 
adjuvant (left) or on the aqueous phase only after vaccine centrifugation (right). The highlighted 
region indicates the accepted range for quantification (80 < %(Cobs/Cexp) < 120).  
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detection chamber. Based on this interpretation, Luminex direct assay was applied 
to TdaP antigens formulated in MF59. The quantification of aP antigens performed 
in the whole MF59 formulation resulted comparable to the one performed in the 
aqueous phase only (Figure 19) thus confirming the initial hypothesis.  
It is known that antigens formulated in MF59 could encounter instability processes 
due to interactions with oil and water interfaces [34]. Despite that, no modification 
in quantification and identification of antigens were detected, suggesting that TdaP 
antigens are compatible with MF59 emulsion adjuvant. 
	
	
 
57	
	
CHAPTER	 I I I . 	 IN 	VIVO 	
EVALUATION	OF	NOVEL	
ADJUVANTS	FOR	 IMPROVED	 	
aP 	COMBINATION	VACCINES 	 	
 
 
“Messieurs, c'est les microbes qui auront le dernier mot"  
Gentlemen, it is the microbes who will have the last word 
- Louis Pasteur 
	
	
	
BORDETELLA 	PERTUSSIS 	
Bordetella pertussis is a Gram negative bacterium of the genus Bordetella, firstly 
observed and isolated at the beginning of the twentieth century by Bordet and 
Gengou [90]. B. pertussis is the etiologic agent of pertussis, a disease which results 
in an acute respiratory tract infection and is usually known as whooping cough since 
it causes severe and incontrollable cough which ends with a whoop when no more 
air is present in the lungs. B. pertussis presents many virulence factors responsible 
for infection and pathogenesis, which are mainly expressed over bacteria surface or 
released in the surrounding environment (Figure 20) [91]. At first, bacteria interact 
and adhere to the cilia of respiratory epithelia cells mainly through the action of 
adhesins such as fimbriae, filamentous hemagglutinin (FHA), and pertactin (PRN or 
69K). Then tracheal cytotoxin is produced to paralyze cilia causing inflammation of 
the respiratory tract and making the cleaning of the infection harder, while pertussis 
toxin (PT) is released to inhibit host immune system by inducing systemic 
pathological effects. 
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Pertussis is a highly contagious disease and vaccination is recognized as the mean 
to potentially eradicate the disease which is still endemic worldwide, despite 
vaccines against pertussis are actually available and recommended. Indeed, the first 
vaccine against pertussis was introduced during the 1940s and contained killed 
whole-cell B. pertussis bacteria (wP) in combination with diphtheria toxoid (DT) 
and tetanus toxoid (TT) inactivated with formaldehyde treatment [6]. The 
introduction of the so-called DTwP vaccine resulted in a drastic decrease in the 
number of reported cases of pertussis disease (Figure 21). However, reactogenicity 
issues and frequent adverse events reduced the confidence in wP vaccines and 
directed scientific efforts towards the development of safer vaccines which resulted 
in the replacement of killed bacteria with purified protective antigens (acellular 
pertussis, aP) [92]. DTaP vaccines were introduced during the 1990s and totally 
replaced whole cell inactivated bacteria (wP) in the USA and in many developed 
countries reaching a vaccination coverage superior than 95% [93, 94]. However, 
FIGURE 20. Schematic representation of Bordetella pertussis bacteria and its main virulence 
factors. Adapted from [91]. 
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following the DTaP vaccine introduction in immunization schedules, a widespread 
pertussis outbreak has been reported in many countries [50-54], despite the 
introduction of a booster vaccine (TdaP) formulated at different dosages for 
adolescents and adults to control herd immunity in all age groups (Figure 21) [95]. 
The observation that the rate of infection was significantly higher among children 
who have been vaccinated with only aP-containing vaccines led to the hypothesis 
that acellular antigens might not provide adequate long lasting protection against 
the disease. Other common hypothesis impute current vaccines to have imposed 
selective pressure on protective antigens thus resulting sub-optimal for current 
circulating strains which have for example evolved to express high levels of PT 
(ptxP3) [96] or to be 69K deficient [97]. Moreover, an increase in the number of 
reported cases could also be correlated with improved disease awareness, 
surveillance, and diagnostic tools [98]. Despite this, the most reliable theory for 
pertussis resurgence claims that aP-containing vaccines induce a waning immunity 
FIGURE 21. Trend of reported cases of pertussis disease following the introduction of DTwP and 
DTaP vaccines. Adapted from: CDC, National Diseases Surveillance System and Supplemental 
Surveillance System and 1922-1949 passive reports to Public Health Service. 
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[99-102] which protects against severe disease but fails to prevent colonization and 
transmission [103].  
Each hypothesis comes along with different approaches to improve current 
vaccination strategies, among which the selection and inclusion of new antigens 
taken either from B. pertussis (e.g. adenylate cyclase toxin, [104]) or from other 
pertussis strains. In this way antigenic divergence and resistance induced by current 
vaccination would be overcome and the possibility to induce protective immunity 
increased [105]. Locht et al [106] even foresee a revival of whole cell vaccines 
attenuated by PT inactivation or by altering lipopolysaccharide (LPS) composition 
thus being less reactogenic. A more straightforward approach considers the 
optimization and improvement of existing aP-containing vaccines avoiding 
extensive work on the discovery of new antigens. The rational design of an 
improved formulation should depend on studies focusing on B. pertussis 
immunogenicity.  
FIGURE 22. Immunogenicity of Bordetella pertussis and immune responses induced by natural 
infection, immunization with whole-cell vaccines, or immunization with acellular pertussis 
antigens. Adapted from [107]. 
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As clearly outlined in Figure 22, natural infections mediated by B. pertussis or 
immunizations with whole cell vaccines are known to induce mainly a cellular 
immune response mediated by Th1 and Th17 cells which is associated with an 
efficient and rapid clearance of B. pertussis and confer high levels of protection 
against subsequent infections. Using a mice infection model Kingston Mills’ group 
showed that protection from B. pertussis colonization correlates with Th1/Th17 
immune profile and subsequent induction of antibodies of the opsonizing IgG2a 
subclass, with activation of macrophages and neutrophils as immune effector cells 
for mediating intracellular killing of B. pertussis [107]. On the other hand acellular 
pertussis vaccines are known to induce a strong humoral immunity with Th2/Th17 
profile, production of toxin neutralizer IgG1 antibodies and activation of 
eosinophils only, which have no known protective role in pertussis immunity [107]. 
This is a reflection of the presence of aluminum salts – known inducers of Th2 
immunity - in aP-containing vaccines, which further polarize immunity towards the 
Th2–type.  
 
EVALUATION	OF	ALTERNATIVE	ADJUVANTS	FOR	IMPROVED		
IMMUNITY	TO	BORDETELLA	PERTUSSIS	
The approaches pursued here to enhance protective efficacy of acellular pertussis 
vaccines are based on the crucial role of Th1-type immune response in clearing B. 
pertussis infection [108, 109]. Thus the improvement of the current formulation 
through the delivery of aP antigens with an appropriate Th1 promoting adjuvant 
was explored. In particular, MF59 emulsion and the combination of a Toll-Like 
Receptor 4 agonist (TLR4a) or of a Toll-Like Receptor 7 agonist (TLR7a) with 
aluminum hydroxide (Alum) were investigated for their ability to enhance 
immunogenicity of a TdaP combination vaccine containing genetically detoxified 
PT toxin (PT-9K/129G) [60], filamentous hemagglutinin (FHA) and pertactin (69K) 
as B. pertussis antigens. 
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MF59 emulsion 
MF59 oil-in-water emulsion [13] was firstly evaluated in a clinical trial for a 
vaccine against influenza in 1992 and after its licensure in 1997 it became the first 
adjuvant approved for human use in alternative to aluminum salts. Since then MF59 
has been extensively evaluated in clinical trials with several different antigens [61, 
110] showing excellent safety and tolerability profiles in all age groups, including 
the elderly and six months old children [111, 112]. In addition, the ability of MF59 
to enhance the humoral or the cellular response - accordingly to the one naturally 
induced by the co-administered antigens [113] - appeared to be beneficial for 
raising a protective immunity against aP antigens.  
Toll-like receptors and their agonists 
As alternative strategy, the inclusion of Toll-like receptor agonists (TLRa) to Alum 
adjuvanted formulations was evaluated. TLRa are molecules which act as immune 
potentiators by directly stimulating antigen-presenting cells (APCs) through binding 
receptors of the innate immune system called pattern recognition receptors (PRRs). 
As a result, local inflammation is induced and additional immune cells are recruited 
to allow stimulation of antigen-specific B- and T-cells and consequently the 
activation of adaptive immunity [114]. Typical ligands of these receptors are highly 
conserved microbial and viral products and their derivatives, defined as pathogen 
associated molecular patterns (PAMPs). For example, TLR4 recognize 
lipopolysaccharide (LPS), TLR5 recognize flagellin, single stranded viral RNAs are 
ligand of TLR7 and TLR8, and CpG motifs are recognized by TLR9 [115]. Because 
of the role of TLRa as immune-potentiators and linker of innate and adaptive 
immune responses, in the past decade a strategy was pursued to exploit natural 
PAMPs for the generation of improved and well-characterized TLR ligands to be 
used as vaccine adjuvants, usually in combination with Alum as a delivery system.  
For the aim of this thesis, Monophosphoryl Lipid A (MPLA) was selected as 
TLR4a. MPLA is a derivative of LPS which retains the immuno-stimulatory 
properties of the natural ligand of TLR4 while lacking toxicity. MPLA is included 
in the adjuvant AS04 [14] and is currently a component in two licensed vaccines 
against human papillomavirus (Cervarix® from GSK) [16] and hepatitis B virus 
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(Fendrix® from GSK) [15]. A synthetic small molecule property of Novartis 
Vaccines was instead used as agonist of TLR7 [116]. Despite differences in 
expression and intra-cellular signaling, TLR agonists have been evaluated in 
numerous preclinical models and are known to increase immunogenicity and 
redirect the immune response induced by Alum toward the stimulation of the Th1-
type against a variety of antigens [117]. 
As mentioned MF59 and Alum+MPLA are the only two novel vaccine adjuvants 
approved for human use after the approval of aluminum salts [118]. Therefore these 
two adjuvants represent attractive options for quickly developing vaccines to fight 
pertussis resurgence, reducing the risk to have the product rejected during clinical 
evaluations. The results obtained with these two alternative adjuvants were gathered 
in a manuscript entitled “The potential of adjuvants to improve immune responses 
against TdaP vaccines: a preliminary evaluation of MF59 and Monophosphoryl 
lipid A” which was submitted to the Clinical and Vaccine Immunology (CVI) 
journal and is reported in the following pages.  
Additional results generated with Alum+TLR7a are presented and discussed in a 
supplementary data section. 
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Abstract 
The successful approach of combining diphtheria, tetanus and pertussis antigens 
into a single vaccine has become the cornerstone of pediatric and adults 
immunization programs. Yet, even if vaccination coverage is high, a resurgence of 
pertussis has been reported recently in many countries suggesting that current 
vaccines may not provide adequate long-lasting protection. 
In order to develop pertussis-containing vaccines able to induce a more durable and 
better tailored immune response different approaches have been proposed, 
including the use of novel adjuvants. Currently licensed pertussis vaccines contain 
aluminum salts, which are the most common adjuvants for human use. By inducing 
mainly humoral immune responses aluminum salts might not be ideal for providing 
protection against pathogens which require a cellular immune response, such as 
Bordetella pertussis.  
Other adjuvants that induce more balanced T-helper profiles or even Th1-prone 
responses might be more adequate. In this study, we tested two different adjuvants: 
MF59 emulsion adjuvant – that induces a mixed Th1/2 response - as well as the 
combination of a Toll-Like Receptor 4 agonist (TLR4a) with aluminum hydroxide 
to induce even further Th1 polarization. The adjuvants were evaluated for their 
ability to improve immune responses against a TdaP vaccine containing three B. 
pertussis antigens: genetically detoxified pertussis toxin (PT-9K/129G), 
filamentous hemagglutinin (FHA) and pertactin (69K).  
The quicker onset of serum titers and the changed quality of the antibody responses 
induced by the adjuvants evaluated here fully support the potential replacement of 
aluminum salts with alternative adjuvants to enhance pertussis immunogenicity in 
aP-containing combination vaccines. 
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Introduction 
The highly contagious respiratory tract infection caused by the Gram negative 
bacterium Bordetella pertussis is still endemic worldwide, despite the fact that 
vaccines are available and recommended. The first pertussis vaccines based on 
whole, killed bacteria (wP) were developed in the 1930s and were later combined 
with diphtheria and tetanus toxoids. The derived DTwP vaccines have been a 
cornerstone of childhood immunization since the 1940s [6]. Effectiveness of DTwP 
vaccination has been documented in numerous clinical trials, but because of 
occurring adverse events the confidence in wP vaccines and vaccination compliance 
decreased with declining case numbers [106]. The efforts to develop safer vaccines 
have resulted in the replacement of inactivated bacteria with purified protective 
antigens of B. pertussis (aP) [7]. These DTaP vaccines have been introduced for 
both primary and booster immunizations [95] and depending on the manufacturer 
contain one to five Bordetella proteins.  
Thanks to the reduced reactogenicity, aP vaccines have totally replaced wP in the 
USA and in many developed countries and vaccination coverage is in excess of 
95% [93, 94].  
However, the number of whooping cough cases started to increase soon after the 
introduction of aP vaccines. Attempts have been made to counter this with 
additional booster vaccines suitable for adolescents and adults (TdaP) since 2005. 
Yet, these just postponed the medium age of pertussis cases from infant to older 
children. Moreover total case numbers have still been increasing over the last years 
[50-54].  
Common hypotheses for the resurgence of pertussis claim that aP vaccines are less 
effective than wP vaccines and that aP-induced immunity wanes more quickly [99-
102]. Also changes in the genetic makeup of circulating pertussis strains have been 
observed [105, 119]. Another plausible explanation has been suggested by a recent 
study showing that aP vaccines protect against severe disease but do not prevent 
infection and transmission of B. pertussis in a nonhuman primate model [103]. 
Therefore little herd immunity should be conferred by aP vaccines on a population 
basis, in contrast to wP vaccines that were shown to shorten B. pertussis 
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colonization in the primate model [103]. An immunological explanation for this 
finding has been extensively assessed in a mouse aerosol challenge model [120]. 
Studying the protection from colonization with different vaccine formulations and 
in various knockout mice this group could show that protection from colonization 
correlates with a Th1/ Th17 immune profile and the induction of antibodies of the 
IgG2a subclass. IgG2a antibodies in mice are known for their better opsonizing 
capacities, in contrast to IgG1 antibodies. Classical aP vaccines induce mainly Th2 
and IgG1 responses and work presumably mostly via toxin-neutralization activity 
[107]. Analysis of the pertussis-induced helper T-cell immune response 
demonstrated that aP vaccination promotes mostly Th2 responses, whereas wP and 
natural infection induce Th1 and Th17 responses [121-123].  
In addition, the currently licensed DTaP vaccines are administered with insoluble 
aluminum salts, which preferentially induce Th2 response [23]. Based on the crucial 
role Th1 response has been found to play in clearing the infection [108, 109] one of 
the proposed approaches to enhance the protective efficacy of aP vaccines considers 
the inclusion of novel Th1-promoting adjuvants in the formulation [106, 124, 125]. 
Several studies have shown that alternative adjuvants to aluminum salts, such as 
micro and nanoparticles, reduced the bacterial loads in comparison to not-
adjuvanted formulations [126] and induced enhanced and persistent responses in 
serum antibody titers against aP antigens [127, 128].   
Here, the emulsion MF59 and the combination of the Toll-Like Receptor 4 agonist 
Monophosphoryl Lipid A (MPLA) with aluminum hydroxide (Alum), in a 
formulation similar to AS04, were evaluated for their ability to adjuvant a TdaP 
trivalent vaccine containing the genetically detoxified PT toxin (PT-9K/129G) [60], 
filamentous hemagglutinin (FHA) and pertactin (69K) as B. pertussis antigens.   
These adjuvants were chosen since they are the only two novel adjuvants already 
included in approved vaccines for human use [118] and represent attractive options 
for fast development of vaccines to counter pertussis resurgence quickly. MF59 is 
an oil-in-water sub-micron emulsion [13, 129] which has been extensively 
evaluated in clinical trials with several different antigens including recombinant 
proteins [110] and bacterial toxoids [61]. The excellent safety and tolerability MF59 
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has demonstrated even in toddlers, infants, and newborns [111, 112] encouraged  its 
evaluation in this work whose focus are combination vaccines for children and 
adolescents. In addition, MF59 adjuvant is able to enhance the humoral or the 
cellular response accordingly to the one naturally induced by the co-administered 
antigens, without biasing the immunological profile [113]. 
As alternative strategy, the inclusion of the MPLA [130] into an Alum-based TdaP 
formulation has been exploited. Acting as PAMPs, the TLRa have been shown to be 
strong vaccine adjuvants improving the immunogenicity of numerous antigens in 
preclinical models [117]. Similar adjuvants are currently licensed for adolescent and 
adult populations but the development for infants might be more challenging as 
compared to MF59. Yet TLRa in association with Alum, in particular the TLR9a 
CpG oligodeoxynucleotide, were found to be highly effective to stimulate Th1 type 
immune response against B. pertussis antigens, including PT and FHA and to 
enhance protective capacity [120, 123]. Therefore, the combination of Alum and 
TLRa might constitute the ideal adjuvant to prime the most adequate responses 
against pertussis.  
The different TdaP-adjuvanted formulations were characterized and compared in a 
mouse model to assess the potential of MF59 and Alum+MPLA respectively to 
enhance and better tailor the immune response against TdaP antigens. 
Materials and Methods 
Antigens and Adjuvants 
Tetanus toxoid (TT) and diphtheria toxoid (DT) were obtained from Novartis 
Vaccines (NV) manufacturing (Marburg, Germany). Genetically detoxified 
pertussis toxin (PT-9K/129G), filamentous hemagglutinin (FHA) and pertactin 
(69K) antigens were produced by Lonza Group (Basel, Switzerland). 
Aluminum hydroxide (Alum) and MF59 adjuvants were obtained from NV 
manufacturing (Marburg, Germany). Toll-Like Receptor 4 agonist (MPLA, 699800) 
was commercially obtained by Avanti Polar Lipids, Inc. (Alabaster, AL). 
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Preparation of adjuvanted formulations 
TdaP antigens 10 Lf TT, 4 Lf DT, 8 μg PT-9K/129G, 8 μg FHA, and 16 μg 69K in 
a volume of 1 ml were adsorbed onto 2 mg/ml Alum suspension [24]. When 
required, MPLA powder was resuspended in 0.5% v/v triethanolamine (TEoA) [131] 
and added to the formulation [132] at the final dose of 10 μg.  
Formulations were adjusted by the addition of 10 mM Histidine buffer and 9 g/l 
NaCl to the recommended physiological ranges of pH and isotonicity.  
For MF59-adjuvanted formulations the TdaP antigens mixture was diluted 1:1 (v:v) 
with MF59 and 10X phosphate buffered saline (PBS) was added to adjust 
formulation pH and isotonicity.  
 
Adjuvanted formulations characterization 
Antigens identity and integrity was evaluated by Western Blot (WB) analysis. 
Briefly, Alum-based formulations were centrifuged (3500 g for 10 min at 25°C) and 
the supernatant removed [61]. The pellet was then resuspended in SDS-extraction 
buffer, boiled and centrifuged. The resulting supernatant was loaded on NuPAGE® 
Novex 4-12% Bis-Tris gels (Life Technologies, Carlsbad, CA). The aqueous phase 
of MF59 emulsion was separated via Airfuge® Air-Driven (Beckman Coulter Inc., 
Pasadena, CA; 70000 rpm for 20 min) and loaded for SDS-PAGE. Gels were run 
for 1 hour at 150 V and then blotted to a nitrocellulose membrane via iBlot® (Life 
Technologies, Carlsbad, CA). Membranes were blocked for 1 hour in 5% w/v 
milk/TPBS (PBS 1X + Tween20 0.05% v/v) and later incubated with optimized 
dilutions of monovalent polyclonal mouse anti-sera generated at NV. Horseradish 
peroxidase-conjugated goat anti-mouse IgG (Southern Biotech, Birmingham, AL) 
was used as secondary antibody (1:5000). After 1-hour incubation at room 
temperature, membranes were washed and Opti-4CN™ Substrate Kit (Bio-Rad, 
Hercules, CA) was used for bands revelation. 
Antigens adsorption onto Alum was evaluated via micro BCA analysis [133] on 
formulation supernatants. A 5-points standard curve was prepared and a formulation 
containing TdaP antigens and the components of the vaccine, except for the 
adjuvants, was included as positive control. 
70	
	
The size distribution of Alum adjuvanted formulations and MF59 emulsion was 
measured by laser light scattering on the LS 13 320 SW (Beckman Coulter Inc, 
Pasadena, CA) and on the Zetasizer Nano ZS (Malvern Instruments Ltd., Malvern, 
UK) instruments respectively. The zeta potential of the formulations was measured 
using the Zetasizer Nano ZS after sample dilution in water. 
Animal experiments 
Animal studies were performed in compliance with the Italian law, approved by the 
local Animal Ethics Committee, and authorized by the Italian Ministry of Health.  
Two similar mouse studies with TdaP antigens formulated with Alum, 
Alum+TLR4a or MF59 respectively were carried out one month a part from each 
other. Groups of 8 female, 6-week-old, specific-pathogen-free BALB/c mice 
(Charles River Laboratories International Inc., Wilmington, MA) were used for the 
studies. Each animal received two intramuscular (i.m.) immunizations at days 1 and 
21. Injections were performed in quadriceps of hind legs for a total dose volume of 
100 μl (50 μl/leg). 
In all studies control groups with non-immunized mice were included. Animals 
were bled two weeks after each immunization and serum samples were analyzed by 
Luminex immunoassay for circulating antibodies titers. Toxin neutralizing antibody 
titers, inhibition of FHA binding activity and IgG subclasses were analyzed after the 
second bleeding. 
Specific IgG measurement using protein-coupled microspheres 
A Luminex penta-plex immunoassay was developed to determine antibody titers in 
mouse sera. In detail, 20 μg of each antigen were coupled to the carboxyl groups of 
1.25 million MagPlex microspheres (Luminex Corporation, Austin, TX) following 
manufacturer's instructions. 
IgG titers were determined in individual animals after 30 min incubation of antigen-
coupled beads with the sera diluted in PBS 1X 1:10000 (post-1) or 1:20000 (post-2) 
into 96-well Multiscreen HTS filter plates (Merck Millipore, Darmstadt, Germany). 
A phycoerythrin-conjugated secondary antibody was then used for detection 
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA; 1:400; 15 min). The 
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obtained immune-complexes were resuspended in PBS 1X and analyzed on the 
Luminex system.  
For IgG subclasses analysis a 30 min incubation step with	 biotin-labeled antibodies 
specific for IgG1 or IgG2a subclasses (Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA; 1:200) was performed after the first reaction between beads and 
diluted sera (1:20000 post-2). Following the incubation with R-Phycoeritrin 
conjugated to extravidin (Sigma-Aldrich, St. Louis, MO; 1:200; 15 min) the 
obtained immune-complexes were resuspended in PBS 1X and analyzed on the 
Luminex system.  
All reaction steps were carried out in agitation motion using a horizontal shaker in 
the dark at room temperature. Among each incubation step, plates are washed three 
times in PBS 1X by a multiscreen vacuum manifold and a Chemical Duty Pump 
(Merck Millipore, Darmstadt, Germany).  
IgG measurements were determined as median fluorescence intensities (MFI) on a 
Luminex FLEXMAP 3D analyzer (Luminex Corporation, Austin, TX) using the 
Bio-Plex Manager 5.0 software (Bio-Rad, Hercules, CA). A hyper-immune 
antiserum specific for each antigen was used as reference to convert MFI values in 
RLU/ml (Relative Luminex Units) for total IgG quantification. The limit of 
quantification (LOQ) of the assay was determined for each antigen and was 
considered as threshold for positive results. 
DT neutralization assay  
Vero cell line (monkey kidney epithelial cells) were obtained from American Type 
Culture Collection (ATCC, Rockville, MD) and maintained in Eagle's Minimum 
Essential Medium (EMEM, Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
heat-inactivated fetal bovine serum (FBS, Gibco, Life Technologies, Carlsbad, CA) 
and antibiotics. Cells were grown at 37°C with 5% CO2.  
The DT-induced cell death was tested by the CellTiter-Glo Luminescent Cell 
Viability Assay (Promega, Madison, WI), based on the measurement of cytoplasmic 
ATP in metabolically active cells. To test the minimal dose of DT needed to cause 
cell death in 16 hours (1 CTU100), cells were plated at 2x104/well in 96-well plates 
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in presence of serially diluted DT (Sigma-Aldrich, St. Louis, MO). The CTU100 was 
defined as 10 ng/ml in the tested experimental conditions.  
Post-2 mouse sera were two-fold serially diluted in cell medium, pre-incubated with 
4 CTU100 of DT toxin and then incubated for 90 min at 37°C. Subsequently, 50 µl 
of Vero cells at density of 2x105cells/ml were incubated with 50 µl of sera and 
toxin mixtures for 16 hours at 37°C. Endpoint titers were defined as the reciprocal 
of the highest dilution able to inhibit cell death. Pre-immune sera were used as 
negative controls. 
PT neutralization assay  
CHO-K1 cell line (Chinese hamster ovary cells) were obtained from American 
Type Culture Collection (ATCC, Rockville, MD) and maintained in F12-K medium 
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Life 
Technologies, Carlsbad, CA) and antibiotics.  
In vitro neutralization assay was optimized following the principles described 
previously [134, 135]. To test the minimal dose of PT needed to cause 100% cell 
clustering in 16 hours (1 CTU100), cells were plated at 2x104/well in 96-well plates 
in the presence of serially diluted PT (Sigma-Aldrich, St. Louis, MO). The CTU100 
was defined as 8 ng/ml in the tested experimental conditions.  
Post-2 mouse sera were diluted and incubated with PT as described for DT 
neutralization assay. Subsequently, 50 µl of CHO-K1 cells at density of 
4x105cells/ml were incubated with 50 µl of sera and toxin mixtures for 16 hours at 
37°C. Cells were observed by light microscopy to evaluate morphological 
alterations (clustered phenotype). Endpoint titers were defined as the reciprocal of 
the highest dilution able to inhibit cell clustering. Pre-immune sera were used as 
negative controls. Sera of mice immunized with commercially available TdaP 
vaccine (Boostrix®, antigens doses 10 Lf TT, 5 Lf DT, 16 μg PT, 16 μg FHA, and 
5 μg 69K in a volume of 1 ml) were included in the assay to evaluate the 
neutralizing effect induced by a chemically detoxified PT toxoid (PTd) included in 
Boostrix®. 
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FHA binding inhibition assay  
A549 cells (Human lung epithelium) were obtained from American Type Culture 
Collection (ATCC, Rockville, MD) and maintained in F12-K medium 
supplemented with 10% heat-inactivated fetal bovine serum (FBS, Gibco, Life 
Technologies, Carlsbad, CA) and antibiotics. Cells were seeded on 96-well plate 
(2.5x104/ well) and cultured for one day. To perform the serum-mediated inhibition 
assay, pooled post-2 mouse sera were two-fold serially diluted in F12-K medium 
containing 1% naïve mouse serum and pre-incubated with 2.5 µg/ml FHA for 1 
hour at 37°C. The mixtures were then added to cells and incubated for 30 min at 
37°C. After extensive washing to remove unbound protein, cells were fixed with 
3.7% paraformaldehyde and incubated with sheep anti-FHA serum (1:500) (NIBSC, 
National Institute for Biological Standards and Control) for 1 hour at room 
temperature. After washings, samples were incubated with Alexa Fluor 488 donkey 
anti-sheep IgG (1:500) (Life Technologies, Carlsbad, CA) and fluorescence 
associated to cell surface was measured at excitation/emission 485/535 nm by 
Tecan Infinite F200PRO microplate reader. 
Statistical analysis 
Graph Pad Prism 5.0 software was used for statistical analysis. Serum antibody 
titers were reported as median while neutralizing titers were reported as mean and 
significant differences (p ≤ 0.05) among groups were ascertained using the two-
tailed Mann-Whitney test at the 95% confidence interval. 
Results 
Adjuvanted formulations characterization  
Vaccines were prepared and characterized to guarantee the quality of the final 
formulations as specified in Materials and Methods. The average particle size of 
Alum suspension was determined to be around 10 µm before and after TdaP 
antigens adsorption (Table VII). When adding MPLA to the vaccine Alum particles 
size doubled and an evident broadening of size distribution was observed. 
Significant reduction of the zeta potential was registered during adsorption of 
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antigens and MPLA onto Alum suspension. MF59 emulsion showed comparable 
particles size, polydispersity and zeta potential at every stage of the formulation 
process (Table VII). TdaP antigens identity and integrity were confirmed by 
Western Blot analysis in Alum as well as in MF59-based formulations. 
Characterization of freshly prepared vaccines gave comparable results to vaccines 
stored up to three months at 4°C (data not shown). To discriminate between Alum-
adsorbed and not-adsorbed antigens, adjuvant was separated by centrifugation. The 
micro BCA performed on the supernatants showed that the adsorption of TdaP 
antigens onto Alum was higher than 95% and that the inclusion of MPLA in the 
formulation did not alter antigens adsorption rate (Table VIII).  
 
Adjuvant TdaP antigens 
Particle size 
(µm± SD) 
Zeta potential 
(mV ± SD) 
Antigen 
adsorption (%) 
Alum 
- 10.8 ± 0.17 25.6 ± 0.87 n.a. 
+ 11.1 ± 0.23 9.50 ± 0.61 > 95% 
Alum+MPLA + 21.6 ± 0.75 -2.50 ± 0.81 > 95% 
MF59 
- 0.15 ± 0.30 -39.0 ± 0.40 n.a. 
+ 0.15 ± 1.00 -38.1 ± 0.81 n.a. 
 
In vivo adjuvant effect  
To assess in vivo potency of the formulations, groups of Balb/c mice were 
vaccinated twice (day 0, 21) and serum antibody titers were measured two weeks 
after each immunization. The analysis of total serum IgG indicated that adjuvants 
were needed to elicit potent immune responses (Figure 22). When antigens were 
formulated in absence of any adjuvant, no response was detected after one 
immunization against TT, FHA and 69K, or in the case of DT neither after the 
second immunization. The only exception was constituted by PT, which was readily 
detected even without any adjuvant after the first immunization. Yet, this might be 
due to the specific properties of the genetically inactivated PT toxin, which is  
TABLE VIII. Physical characterization of various vaccine formulations. N.a. not applicable. 
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FIGURE 23. Serum (a) anti-TT, (b) anti-DT, (c) anti-FHA, (d) anti-69K, (e) anti-PT antibody 
titers in Balb/C mice after one and two immunizations at days 1 and 21. Averaged results of the 
two mouse studies are shown as median with interquartile range presented for each group.  
•  serum IgG titers below 1 RLU/ml; LLOQ ≤ 0.9 RLU/ml; * p < 0.05, ** p < 0.01, *** p < 0.001    
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known to be more immunogenic as compared to its chemically detoxified 
counterpart included in commercially available aP vaccines [60, 136]. Further 
explanation could be associated with the intrinsic adjuvant activity that the 
genetically detoxified PT was shown to harbor [137, 138]. Serum IgG analysis 
revealed that two immunizations with Alum-adjuvanted formulations were required 
to induce detectable IgG titers against DT and FHA antigens. 
Similar results were also observed when including MF59 adjuvant in the vaccine. 
For the other antigens (TT, PT, 69K) MF59 was instead shown to be superior to 
Alum after a single immunization and the trend was confirmed after the second 
immunization. Serological analysis performed on the first bleeding for DT and FHA 
antigens indicated Alum+MPLA as the only adjuvant able to raise detectable 
responses. Overall, a single immunization with Alum+MPLA adjuvant induced IgG 
titers higher than the ones induced by Alum. As previously stated, PT-9K/129G was 
the only antigen to be immunogenic after a single immunization without any 
adjuvantsand resulted as effective as Alum. On the contrary, the alternative 
adjuvants tested were shown to have comparable adjuvant activity while raising 
significantly higher IgG responses in comparison to Alum. For the other TdaP 
antigens Alum+MPLA adjuvanticity was superior to MF59. As a whole, post-1 data 
depicted Alum+MPLA as the most potent adjuvant inducing quicker onset of the 
immune response and higher antibody titers against TdaP antigens, while MF59 
performed at least as effectively as Alum. 
After the second dose Alum+MPLA confirmed its stronger adjuvanticity as 
compared to Alum. In addition, Alum+MLPA was also more effective than MF59 
for DT antigen confirming Alum as a successful adjuvant for this bacterial toxoid. 
On the contrary, formulations adjuvanted with Alum+MLPA or MF59 resulted in 
comparable responses against PT and FHA and MF59 was shown to be the most 
effective adjuvant for TT and 69K antigens.  
On the basis of the serological responses at both vaccine doses, both the approaches 
investigated could be considered as promising alternatives to Alum in TdaP 
vaccines.	 
 
77	
	
DT and PT toxin neutralizing activity 
To evaluate the ability of the induced antibodies to recognize antigenic functional 
epitopes, different toxin neutralization assays were performed after the second 
bleeding. The neutralization assay against DT indicated that Alum+MPLA was able 
to stimulate significantly higher neutralizing titers in comparison to Alum (Figure 
24a). 
In contrast, pertussis toxin neutralizing assay showed that the use of adjuvants in 
the formulation did not lead to significant enhancement of the neutralizing activity 
of anti-PT antibodies (Figure 24b). 
As previously noticed for total serum antibody titers, this might be explained by the 
strong immunogenic properties of this antigen. In fact, evident differences in 
FIGURE 24. Post-2 in vitro neutralization titers (a) anti-DT and (b) anti-PT. (c) comparison of 
the neutralizing activity of genetically detoxified PT-9K/129G and chemically detoxified PT 
(PTd) included in Boostrix vaccine. Mean with standard deviation presented for each group.  
• titers below detection limit. * p <0.05, *** p <0.001
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neutralizing activity were observed when comparing TdaP formulations containing 
the genetically detoxified PT to Boostrix® vaccine in which a chemically detoxified 
PT (PTd) is used (Figure 24c). Notably, PT-9K/129G induced significantly higher 
neutralizing titers despite being formulated at half of the dose of PTd, further 
supporting the potential of PT-9K/129G as candidate antigen to develop improved 
vaccines against pertussis.  
 
FHA binding inhibition 
FHA is an important adhesion factor of Bordetella pertussis and the inhibition of its 
binding to ciliary epithelial cells is of significant relevance to prevent pathogen 
adherence to the host respiratory tract. Achieving higher adhesion blocking 
antibodies should therefore contribute to greater protection from bacterial 
colonization and so from contracting the disease [139]. 
The adjuvant effect on the induction of antibodies able to block FHA binding 
activity was evaluated on pooled sera after the second immunization and indicated 
that Alum+MPLA and MF59 equally improved the inhibition activity of anti-FHA 
antibodies in comparison to Alum (Figure 25).	 
Shift in the IgG1/ IgG2a profile 
Alternative adjuvants to Alum were investigated for their ability to induce a more 
Th1 oriented immune response against aP antigens using TdaP as a model vaccine. 
FIGURE 25. FHA binding activity of pooled post-2 sera of mice immunized with different 
formulations.  Mean with standard deviation presented for each group. FI: fluorescence intensity 
at excitation/emission 485/535 nm. 
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FIGURE 26. Median fluorescence intensities (MFI) relative to specific IgG1 and IgG2a responses 
(a) anti-TT, (b) anti-DT, (c) anti-FHA, (d) anti-69K, (e) anti-PT in Balb/C mice after two 
immunizations. Median with interquartile range presented for each group.  •  values below 1 MFI. 
(b) 
(d) 
(a) 
(e) 
(c) 
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In the mouse model, a Th2 response is correlated to IgG1 antibodies, while Th1 
responses are characterized by the subclass IgG2a, b or c (depending on the 
individual mouse strain). Classical aP vaccines induce mainly Th2 and IgG1 
responses and work presumably mostly via toxin-neutralization activity [107]. In 
contrast, IgG2a, b or c antibodies are known for their better opsonizing capacities 
and should account, together with the phagocyte-activating-cytokine-secreting Th1 
cells, for the improved bacterial clearance shown in the mouse model [120, 140]. 
To assess a potential shift in the IgG1/IgG2a balance and hence quality of the 
immune response, antibody subclasses were analyzed after the second 
immunization. As expected Alum induces a more Th2-prone response with reduced 
IgG2a and enhanced IgG1 titers in comparison to the not-adjuvanted formulation, 
as can be readily observed for FHA and PT. For the other antigens the overlaying 
adjuvant effect of Alum, enhancing all titers, make a comparison of a potential shift 
less assessable. Importantly a shift to a more IgG2a/Th1 prone profile was observed 
as compared to Alum when combining Alum and MPLA or using MF59 emulsion. 
Both adjuvants clearly enhanced IgG2a titers against the five TdaP antigens and, as 
expected, MF59 was shown to maintain the natural immunological profile of the 
antigens (Figure 26). On the contrary, Alum adjuvant completely reset the intrinsic 
Th1 inducing effect showed by FHA and PT antigens. The ability of MPLA to 
redirect the immune response against these antigens appeared evident through the 
reversion of the quality of the immune response when the immune-potentiator was 
combined with Alum.  
Discussion 
Despite a generally high vaccination coverage there is a recent resurgence of 
pertussis in many countries worldwide. Several hypotheses have been formulated 
but most experts agree that waning immunity and inadequate immune profiles 
induced by acellular vaccines are to blame, next to changes in the genetic makeup 
of circulating pertussis strains. Induction of a Th1 profile – as induced by wP 
vaccines or actual infection - is seen as beneficial to protect from bacterial 
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colonization and to enhance herd immunity. In contrast, currently available 
acellular vaccines mainly induce a Th2-prone response.  
Future pertussis vaccines should have a safety profile similar to current acellular 
pertussis-containing vaccines, but ideally induce longer lasting immunity and more 
adequate T-helper response profiles. Therefore in this study the potential of 
alternative adjuvants to aluminum salts to enhance the efficacy of aP vaccines was 
assessed, and two different approaches that have already been successfully used in 
human vaccinations were chosen. 
On the basis of the well-established safety of MF59 emulsion [141] and of the 
strong immunological stimulation induced by TLRa [142], TdaP formulations 
adjuvanted with MF59 or with the TLR4 agonist Monophosphoryl lipid A (MPLA) 
in combination with Alum have been studied. The possibility to develop stable and 
defined formulations has been evaluated through the physical characterization of 
TdaP formulations and the investigation of their in vivo immunogenicity and 
individual immune profile. 
With respect to quantity, quality and functionality of the induced immune responses 
both alternative approaches created a promising scenario for the development of 
next generation aP containing vaccines. 
The adjuvant effect of MF59 resulted in immune responses against TdaP antigens 
higher or at least comparable to Alum. This finding, along with the demonstrated 
enhancement of antibody responses against other antigens routinely included in the 
pediatric immunization schedules, such as those from Haemophilus influenzae type 
b	 (34) and hepatitis B virus (35), show the strong potential of MF59-adjuvanted 
TdaP vaccines to be readily further developed to improve current infant-pertussis 
combination vaccines. As revealed from the unchanged results of size distribution 
and zeta potential pre- and post-formulation, TdaP antigens remained mostly free in 
the aqueous phase of MF59 emulsion. Despite this condition could possibly induce 
instability processes [34], no modification in the antigenic electrophoretic profiles 
were detected suggesting TdaP antigens are compatible with MF59 adjuvant.  
Antigens adsorption on adjuvant surface is instead one of the main feature of 
formulations based on aluminum salts and it is considered a very important 
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parameter for their function [26, 32], such that WHO recommended adsorption 
values equal or greater than 80% for diphtheria and tetanus toxoids [84]. The 
reduction of the zeta potential registered during formulation procedure confirmed 
TdaP antigens are adsorbed onto Alum adjuvant, condition known to ensure 
antigens stability in liquid vaccine formulations. Further proof came from micro 
BCA analysis, which measured in supernatants of formulation less than 5% of the 
total antigenic amount formulated, thus indicating only a minor part of antigens 
remained not-adsorbed to the adjuvant. In addition, TdaP antigens adsorption rate 
onto Alum was not modified when including MPLA in the formulation. Aluminum 
salts have been previously shown to induce enhanced and better modulated immune 
responses when combined with TLR agonists through the co-administration of both 
antigens and agonists to the same antigen presenting cell [14, 143, 144]. In addition 
Geurtsen et al. [145] demonstrated that aP vaccine adjuvanted only with MPLA 
were more protective than aP vaccines containing Alum. Yet, safety concerns have 
been raised for formulations where MPLA is not adsorbed to a delivery system like 
Alum or nanoparticles. Moreover, several other studies demonstrated that MPLA in 
combination with Alum adjuvant resulted in more potent immune responses and 
recommended MPLA adsorption onto Alum surface to prevent potential systemic 
toxicity [22]. In this context, the adjuvanticity of Alum in combination with the 
immune-potentiator MPLA for a TdaP trivalent vaccine has been exploited. Beyond 
the overall higher serum titers raised by the inclusion of MPLA in the formulation 
in comparison to Alum, Alum+MPLA was also shown to accelerate the onset of the 
immune responses suggesting that the addition of a TLR agonist to Alum-based 
formulations could potentially reduce the number of injections required to ensure aP 
vaccine immunogenicity.  
A crucial parameter to develop a highly effective vaccine against pertussis is to 
induce high antibody titers against PT, one of the major virulence factors of B. 
pertussis. In this perspective, the inclusion of PT 9K/129G in future pertussis 
combination vaccines appears promising also considering that the genetically 
modified toxin has already been shown to retain higher immunogenicity than the 
chemically detoxified PT (PTd) included in the currently licensed vaccines [60, 
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146]. Furthermore, PT 9K/129G has been identified as ideal vaccine candidate since 
it cannot revert to toxicity while conserving the native B and T cell epitopes which 
may be lost during a chemical detoxification [147] and has been reported to have an 
intrinsic adjuvant activity in mice [137, 138]. The adjuvant effect for PT 9K/129G 
was less evident in comparison to what was observed for the other antigens of the 
combination, however significant improvement in terms of total IgG antibody titers 
was detected in presence of MPLA. Dose titration studies of PT antigen are planned 
to provide more detailed insights on the direct effect of TLRa and MF59 adjuvants 
on its immunogenicity. 
To assess if the alternative adjuvants tested in the current work were effective in 
inducing Th1 response, the induction of opsonizing IgG2a was evaluated and taken 
as indirect evidence of enhanced cell mediated responses. In literature those 
responses are associated with an efficient and rapid clearance of B. pertussis [120] 
and with the superior long term protection of wP vaccination [148]. As expected, 
Alum+MPLA strongly potentiated the Th1 immune response leading to increased 
IgG2a antibody titers. Interestingly, an appreciable enhancement of IgG2a titers 
against TT and B. pertussis surface adhesins was also observed with MF59 
emulsion thus confirming the peculiarity of this adjuvant to strengthen the immune 
responses naturally induced by the co-administered antigens [113]. The observed 
stimulation of Th1-type immune response against B. pertussis surface adhesins is 
encouraging for the improvement of aP-containing vaccines efficacy since these 
antigens are reported amongst the main mediators of pathogen colonization and 
transmission [103].  
Considering that both Alum+MPLA and MF59 adjuvants have been proven to be 
valuable approaches in the mouse model, it would be interesting to further 
investigate if the adjuvant effect on pathogen colonization and immune response 
persistence could be answered in the baboon model which has emerged as an 
appropriate animal model to reproduce all aspects of pertussis clinical disease [103].  
Overall, the high antibody titers against PT and the promotion of a Th1-oriented 
response against B. pertussis surface adhesins obtained with the alternative 
formulations developed are initial encouraging data fully supporting the potential of 
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adjuvants to raise better tailored immunological responses against aP-containing 
combination vaccines and to effectively control pertussis spread and overcome 
waning immunity issues. The critical adjuvant selection relying on adjuvants 
already licensed in vaccines for infants and toddlers, such as MF59, or on the 
addition of a TLR agonist to existing formulations, emerged as a simpler and faster 
approach for better vaccine development than the identification of entirely new 
vaccine candidates. 
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SUPPLEMENTARY	DATA	
	
EVALUATION	OF	A	SYNTHETIC	AGONIST	OF	TOLL‐LIKE	RECEPTOR	7	
Pursuing Novartis Vaccines’ strategy of using SMIP (small molecule immune-
potentiators) as agonist to activate immune cells through the targeting of Toll-like 
Receptor 7 (TLR7), a synthetically obtained TLR7 agonist (TLR7a) was evaluated 
for its adjuvant effect when included in Alum adjuvanted vaccine formulations. A 
soluble agonist was designed and functionalized with PEG linker and a terminal 
phosphonate group to allow adsorption to aluminum hydroxide via ligand exchange 
with the aim of limiting SMIP’s systemic exposure while ensuring co-localization 
of antigens and adjuvants and favoring retention time in the muscle for interaction 
with immune cells [116]. 
Materials and Methods 
Only deviations from the procedures described in the previously reported 
manuscript are included in this section. 
Antigens and Adjuvants 
Toll-Like Receptor 7 agonist was internally synthetized by the Genomic Institute of 
the Novartis Research Foundation (GNF). 
Preparation of adjuvanted formulations 
TdaP antigens (10 Lf TT, 4 Lf DT, 8 μg PT, 8 μg FHA, and 16 μg 69K) were 
adsorbed onto 2 mg/ml Alum suspension [24] to a final volume of 1 ml. When 
required, TLR7a was added to the formulations at 50 μg per dose. Animals were 
immunized intramuscularly with a total volume of 100 μl (50 μl/leg).  
TLR7a identity and degree of adsorption onto Alum adjuvant 
TLR7a identity and adsorption rate onto Alum were assessed via reverse phase 
ultra-performance liquid chromatography (RP-UPLC) analysis. Briefly, after 
spinning down the vaccine, the supernatant was removed and aliquots of 7.5 µl 
were injected in the UPLC system. The pellet was resuspended in 500mM 
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potassium phosphate buffer (P3786 Sigma Aldrich) pH 9.0 and incubated at 95°C 
for 10 min. After Alum separation via centrifugation, the resulting supernatant was 
appropriately diluted and 7.5 µl were used for UPLC analysis. TLR7a separation 
was achieved by using a 50mm x 2.1mm, 1.7µm particle size, Acquity UPLC® 
BEH-C18 column (Waters). The mobile phase was a 10 to 90% acetonitrile gradient 
prepared in water added of 0.1% trifluoroacetic acid (TFA) at a flow rate of 1.2 
mL/min.  268 nm UV was used for TLR7a detection. Detection and quantification 
limits of the method were found to be 0.39 µg/ml and 0.78 µg/ml respectively. 
Results and Discussion 
Similarly to what observed with Alum+MPLA and MF59 adjuvants, Alum+TLR7a 
proved to be a valuable approach for improving pertussis immunogenicity in the 
mouse model, too. Antigens adsorption onto Alum was estimated to be higher than 
90% by WB analysis: none of TdaP antigens was in fact detectable in the 
supernatants of Alum or Alum+TLR7a formulations even after protein 
concentration via TCA (data not shown). Overall the inclusion of TLR agonists in 
Alum formulations was shown not to modify TdaP-antigens adsorption profile. 
Adsorption rate of TLR7a onto Alum was calculated by using a five-point 
calibration curve and was found to be higher than 95%. TLR7a identity and 
integrity was confirmed after desorption from Alum. In addition, RP-UPLC 
analysis of the desorbed TLR7a allowed a recovery higher than 95% of the agonist 
(data not shown). The agonist was always tested in combination with Alum 
adjuvant to prevent systemic adverse events. Moreover, previous studies showed 
that SMIP alone was inefficient in the induction of protective antibodies against 
tested antigens [116].  
 
In vivo adjuvant effect 
To assess in vivo potency of Alum+TLR7a, groups of Balb/c mice were vaccinated 
twice (day 0, 21) and serum antibody titers were measured before and two weeks 
after each immunization. Observations made for Alum+MPLA resulted to be valid 
also for Alum+TLR7a and serological analysis for DT and FHA antigens performed  
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FIGURE 27. Serum (a) anti-TT, (b) anti-DT, (c) anti-FHA, (d) anti-69K, (e) anti-PT antibody 
titers in Balb/C mice after one and two immunizations at days 1 and 21. (f) anti-PT antibody titers 
in Balb/C mice immunized at days 1 and 28. Results are shown as median with interquartile range 
presented for each group.  
•  serum IgG titers below 1 RLU/ml; LLOQ ≤ 0.9 RLU/ml; * p < 0.05, ** p < 0.01, *** p < 0.001    
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on serum samples taken after the first immunization revealed that the combination 
of Alum with the agonist was the only strategy able to induce detectable antibody 
responses. Overall, a single immunization with Alum+TLR7a adjuvant raised IgG 
titers higher than the ones induced by Alum. The immune potentiator role of the 
TLR7 agonist was particularly evident for aP surface adhesins leading to titers 
comparable to those raised by two immunizations with the non-adjuvanted antigens. 
After the second dose Alum+TLR7a confirmed its stronger adjuvanticity in 
comparison to Alum for all the tested antigens with the exception of PT. The 
observation about the less pronounced adjuvant effect for PT was already described 
in the manuscript above and justified by the strong immunogenic properties of this 
antigen. Follow-up studies performed with Alum+TLR7a adjuvant increasing the 
number of immunized animals and extending the injection schedule from day 0, 21 
to day 0, 28 made the adjuvant effect more evident and significantly higher than the 
on induced by Alum (Figure 27).  
Neutralizing activity 
To evaluate the ability of the induced antibodies to recognize functional epitopes of 
the antigens, toxin neutralization assays were performed after the second bleeding. 
Again, the combination of TLR7 agonist with Alum adjuvant stimulated 
significantly higher neutralizing titers against DT in comparison to Alum, while not 
providing an enhancement of neutralizing activity against PT. As previously noticed 
for total serum antibody titers, increasing the number of immunized animals and the 
interval between the two injections allowed the observation of an adjuvant effect for 
PT antigen (data not shown).  
Shift in the IgG1/ IgG2a profile 
Alum+TLR7a was investigated as alternative adjuvant to Alum for its ability to 
induce a more Th1 oriented immune response against aP antigens in TdaP vaccine. 
Classical Alum adjuvanted aP vaccines induce mainly Th2 responses with 
antibodies of the IgG1 subclass and work presumably mostly via toxin-
neutralization activity [107]. In contrast, Th1 responses are characterized by the 
subclass IgG2a, b or c (depending on the individual mouse strain) which are known  
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FIGURE 28. Median fluorescence intensities (MFI) relative to specific IgG1 and IgG2a responses 
(a) anti-TT, (b) anti-DT, (c) anti-FHA, (d) anti-69K, (e) anti-PT in Balb/C mice after two 
immunizations. Median with interquartile range presented for each group.  •  values below 1 MFI. 
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for their better opsonizing capacities and should improve bacterial clearance [120, 
140]. To assess a potential shift in the IgG1/IgG2a balance and hence quality of 
serum antibody responses, subclasses were analyzed after the second immunization. 
The immune-potentiator role of TLR4a in inducing a shift to a more protective Th1 
(IgG2a) profile was observed also for TLR7a when combined to Alum (Figure 28). 
As already stated, an enhancement of the Th1-type immune response is associated 
with a more efficient clearance of B. pertussis and with an extended protection like 
the one induced by wP vaccines or natural infection [120, 148]. 
In addition, preliminary evaluation of the stimulation of memory B cells was 
performed. However despite a visible trend indicating the immune-stimulatory 
effect of TLR7a the assay needs to be further improved – data not shown. 
Dose-titration and antibody duration studies 
Alum+TLR7a was selected as internal strategy for the development of improved 
acellular pertussis combination vaccines thus being used as main alternative 
adjuvant in follow-up studies. Immunization schemes were arranged vaccinating 
Balb/c mice twice (day 0, 28) with different doses of TdaP antigens and of TLR7 
agonist in combination with Alum. Dose-titration studies revealed that similar 
results could be obtained using ten times less antigen doses with respect to the 
doses used in the previous studies (see paragraph Preparation of adjuvanted 
formulations). Also the dose of the immune-potentiator could be reduced to 10 
µg/injection while maintaining comparable results. Importantly, together with an 
enhancement in quantity, total antibody titers as well as IgG2a-specific antibodies 
were found to persist up to ten months after the last immunization (data not shown).  
Evaluation of larger TdaP-based combination vaccines 
The feasibility to develop larger TdaP-based combination vaccines was evaluated 
through the co-administration of TdaP antigens together with three recombinant 
antigens conferring protection against Neisseria meninigitidis type B. Analysis of in 
vivo immune responses conveyed that the presence of additional antigens in the 
vaccine combination had no negative interference on the quantity of antibody titers 
raised against TdaP antigens (Figure 29).  
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Conclusions 
Results obtained using Alum+TLR7a as improved adjuvants for TdaP vaccine 
provided encouraging prospective of raising enhanced and better tailored 
immunological responses against aP-containing combination vaccines. TLR7a 
molecule is chemically and structurally defined and was specifically designed to be 
recognized by specific receptors thus stimulating the immune response. In 
comparison to MPLA, the synthetically obtained molecule TLR7a has the 
advantage of being structurally simpler thus potentially leading to more 
reproducible results, both in terms of vaccine formulations and induced immune 
responses. 
  
FIGURE 29. Serum anti-FHA and anti-69K antibody titers are taken as representative of all the 
five TdaP antigens. Results were obtained in Balb/C mice after two immunizations with TdaP or 
TdaP+MenB antigens. Median with interquartile range is shown for each group. 
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CHAPTER	 IV . 	CONCLUSIONS	
 
 
 
 
 
 
 
 
The objective of this PhD work was to investigate the possibility of improving 
quality and immunogenicity of current acellular pertussis combination vaccines, 
which are combined with diphtheria and tetanus toxoids in the keystone of 
combination vaccines. Vaccines and combination vaccines in particular, are 
complex multi-component products whose efficacy relies on the concomitant 
inclusion of antigens, adjuvants, and excipients. Currently licensed aP vaccines are 
typically adjuvanted with aluminum salts, known to induce mainly a humoral 
immune response which has been associated with the recent pertussis outbreaks 
reported in many countries. Therefore, existing vaccines are perceived as not ideal 
to provide protection against the disease. A formulation science approach was here 
proposed and developed to investigate the potential improvement of acellular 
pertussis vaccines by working on the adjuvant component. In particular, the 
promotion of the vaccine analytical characterization and the rational polarization of 
the quality of immune responses were suggested as effective strategies to be 
pursued for the development of improved combination vaccines. 
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Improved in vitro characterization assays for combination vaccines adjuvanted 
with aluminum hydroxide 
In Chapter II significant progresses for the in vitro characterization of complex 
aluminum salts-adjuvanted vaccines were introduced. In particular, the possible use 
of Luminex technology for vaccine characterization purposes was exploited and 
developed in a multi-plex microsphere-based immunoassay for simultaneous 
analysis of aP antigens in TdaP vaccines. In a single experiment, the proposed assay 
provided - information on antigen identity, quantity, and degree of adsorption to 
adjuvant surface of each immunogen included in a multivalent combination. The 
simultaneous characterization of the three aP antigens was performed directly on 
the whole TdaP vaccine without any preliminary treatment of the adjuvant or 
laborious procedures for adjuvant separation, as commonly required for available 
analytical methods. The assay relied on antibody recognition and fluorescence 
detection, thus demonstrating specificity and providing a substantial improvement 
in terms of sensitivity as compared with other commonly used immunoassays. 
Importantly, the high sensitivity of the Luminex assay allowed precise 
quantification of low amounts of antigens not-adsorbed to adjuvant surface. 
Polyclonal antibodies were used as proof of concept in this work. Their replacement 
with appropriately selected monoclonal antibodies could allow the qualitative 
analysis of antigenic epitopes critical for vaccine immunogenicity. In this 
perspective, the possibility to correlate quality of antigenic components with the 
efficacy of the product could lead to the set-up of an in vitro potency assays 
accordingly to the 3Rs concept. Moreover, the Luminex-based approach has the 
potential to be implemented for larger vaccine combinations and to be applied in 
presence of other adjuvants and delivery systems, such as emulsions and polymeric 
particles.  
In vivo evaluation of novel adjuvants for improved aP-containing combination 
vaccines 
Chapter III was dedicated to study aP vaccine efficacy and the possibility of 
tailoring immune responses by the modulation of the vaccine formulation. Despite 
generally high vaccination coverage a pertussis outbreaks are registered in many 
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countries worldwide. The most reliable hypothesis for pertussis resurgence claims 
that waning immunity and inadequate immune profiles induced by acellular 
vaccines are to blame. Induction of a Th1-type immune response - as induced by 
wP vaccines or natural infection - is seen as beneficial to protect from bacterial 
colonization and to enhance herd immunity. In contrast, currently available 
acellular vaccines mainly induce a Th2-type response. In this perspective, MF59 
emulsion and two different TLR agonists in combination with aluminum salts were 
critically selected as alternative adjuvants for acellular pertussis antigens. 
Alternative approaches tested created a promising scenario for the development of 
next generation aP containing vaccines with respect to quantity, quality and 
functionality of the induced immune responses. Importantly, high antibody titers 
against PT and the promotion of a Th1-oriented response against B. pertussis 
surface adhesins were obtained with the alternative formulations developed. 
Moreover, the addition of a TLR agonist to Alum-based formulations was shown to 
accelerate the onset of the immune responses suggesting the potential to reduce the 
number of injections required to ensure aP vaccine immunogenicity. Encouraging 
data were obtained supporting the potential of adjuvants to raise better tailored 
immunological responses against aP-containing vaccine combinations and to 
effectively control pertussis spread and overcome waning immunity issues. The 
modulation of vaccine formulation through careful selection of adjuvants has thus 
emerged as a straight forward approach for the development of effective vaccines.  
Overall, advancing the analytical characterization of vaccines on one side and 
inducing rational polarization of immune responses on the other were presented as 
suitable approaches to improve both quality and efficacy of future vaccines. 
Accordingly, the optimization of complex vaccine products through the rational use 
of adjuvants was proposed as a promising strategy for the development of next 
generation vaccines. 
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